hydroxychloroquine has been researched along with lopinavir in 210 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 210 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Chen, J; Chen, W; Choudhry, N; Xu, D; Yang, Z; Zanin, M; Zhao, X | 1 |
| Easwaran, M; Manickam, M; Pillaiyar, T; Wendt, LL | 1 |
| Chen, J; Gao, K; Huang, F; Tepe, JJ; Wang, R; Wei, GW | 1 |
| Baden, LR; Morrissey, S; Rubin, EJ | 1 |
| Duan, Y; Zhou, C; Zhu, HL | 1 |
| Cohen, J; Kupferschmidt, K | 1 |
| Cravedi, P; Degli Antoni, A; Delsante, M; Fiaccadori, E; Gandolfini, I; Maggiore, U; Manenti, L; Peruzzi, L; Riella, LV; Zaza, G | 1 |
| Chang, YL; Chen, MY; Lee, WS; Lu, CC | 1 |
| Barlow, A; Barlow, B; Claassen, CW; Heavner, JJ; Heavner, MS; Landolf, KM; Yeung, SYA | 1 |
| Al-Tawfiq, JA; Memish, ZA | 1 |
| Bagalà, A; Bartiromo, M; Bartoloni, A; Borchi, B; Botta, A; Bresci, S; Cavallo, A; Cirami, C; Cutruzzulà, R; Larti, A; Lugli, G; Tilli, M; Vaglio, A; Xhaferi, B | 1 |
| Cutrell, JB; Jodlowski, TZ; Monogue, ML; Sanders, JM | 1 |
| Şimşek Yavuz, S; Ünal, S | 1 |
| Costanzo, M; De Giglio, MAR; Roviello, GN | 1 |
| Doan, T; Oldenburg, CE | 1 |
| Aguado, JM; Andrés, A; Delgado, JF; Fernández-Ruiz, M; Folgueira, MD; González, E; Lalueza, A; Loinaz, C; López-Medrano, F; Lumbreras, C; Polanco, N; San Juan, R | 1 |
| Hsueh, PR; Jean, SS; Lee, PI | 1 |
| Choi, SW; Kang, S; Lee, S; Lim, DH; Seo, KW; So, MW; Song, J | 1 |
| Aryal, D; Beane, A; Dondorp, AM; Hayat, M; Schultz, MJ | 1 |
| Ahsan, W; Alhazmi, HA; Bratty, MA; Javed, S; Najmi, A | 1 |
| Han, S; Hyun, M; Jin, K; Kim, HA; Kim, Y; Kwon, O; Lee, JY; Paek, JH; Park, WY | 1 |
| Dhochak, N; Kabra, SK; Lodha, R; Sankar, J | 1 |
| Ardura, M; Auletta, JJ; Dandoy, C; Hartley, D; Jaglowski, S; Lehmann, L | 1 |
| Ackerman, MJ; Friedman, PA; Giudicessi, JR; Noseworthy, PA | 1 |
| Azzari, C; Bortone, B; Casini, T; Favre, C; Galli, L; Moriondo, M; Pegoraro, F; Sieni, E; Tondo, A | 1 |
| Carretero-Barrio, I; Fernandez-Nieto, D; Jimenez-Cauhe, J; Moreno-Garcia Del Real, C; Ortega-Quijano, D; Saceda-Corralo, D; Suarez-Valle, A | 1 |
| Ahn, JH; Choi, EY; Chung, JH; Hong, KS; Jang, JG; Jin, HJ; Lee, KH; Lee, W; Shin, KC | 1 |
| Besutti, G; Bonacini, R; Dolci, G; Guaraldi, G; Iotti, V; Ligabue, G; Maiorana, M; Marini, G; Massari, M; Monelli, F; Pattacini, P; Riva, N; Rossi, PG; Spaggiari, L | 1 |
| Gadebusch Bondio, M; Marloth, M | 1 |
| Anastasiou, IA; Eleftheriadou, I; Tentolouris, A; Tentolouris, N; Tsilingiris, D | 1 |
| Wang, Y; Xia, T | 1 |
| Abdullah, MS; Asli, R; Chong, PL; Chong, VH; Mani, BI; Metussin, D; Momin, RN | 1 |
| Anselmi, E; Cavanna, L; Citterio, C; Codeluppi, M; Stroppa, EM; Toscani, I; Zaffignani, E | 1 |
| Andini, R; Bertolino, L; Corcione, A; Durante-Mangoni, E; Florio, LL; Mele, F; Murino, P; Zampino, R | 1 |
| Ashton, NJ; Blennow, K; Caruso, A; Castelli, F; Comelli, A; Focà, E; Gasparotti, R; Gazzina, S; Leonardi, M; Masciocchi, S; Nocivelli, S; Odolini, S; Padovani, A; Pasolini, MP; Pezzini, A; Pilotto, A; Volonghi, I; Zetterberg, H | 1 |
| Estella, Á; Garnacho-Montero, J | 1 |
| Marto, N; Monteiro, EC | 1 |
| Aggarwal, G; Aggarwal, S; Bangalore, S; Henry, BM | 1 |
| Aliberti, S; Blasi, F; Bollati, V; Di Cosola, R; Ratti, A; Rota, F; Rota, I; Ruscica, M; Vicenzi, M | 1 |
| Atzrodt, CL; Clements, TP; Maknojia, I; McCarthy, RDP; Oldfield, TM; Po, J; Stepp, HE; Ta, KTL | 1 |
| Bertazzoni, G; Lund, VJ; Mangiatordi, F; Morello, R; Pianta, L; Trimarchi, M; Vinciguerra, A | 1 |
| Bottiroli, M; Buscemi, V; Calini, A; Centonze, L; De Carlis, L; De Carlis, R; Fumagalli, R; Lauterio, A; Merli, M; Puoti, M; Santambrogio, S; Valsecchi, M | 1 |
| Alffenaar, JW; Andréjak, C; Bachez, P; Bart, PA; Belilovski, E; Blanc, FX; Borisov, S; Cardoso-Landivar, J; Centis, R; Codecasa, LR; D'Ambrosio, L; Dominguez-Castellano, A; Dourmane, S; Fréchet Jachym, M; Froissart, A; García-García, JM; Giacomet, V; Goletti, D; Grard, S; Gualano, G; Izadifar, A; Le Du, D; Luiza De Souza-Galvão, M; Marín Royo, M; Mazza-Stalder, J; Migliori, GB; Motta, I; Ong, CWM; Palmieri, F; Rivière, F; Rodrigo, T; Sánchez-Montalvá, A; Saporiti, M; Scarpellini, P; Schlemmer, F; Silva, DR; Sotgiu, G; Spanevello, A; Sumarokova, E; Tabernero, E; Tadolini, M; Tambyah, PA; Tiberi, S; Torre, A; Visca, D; Zabaleta Murguiondo, M | 1 |
| Habibzadeh, P; Lankarani, KB; Moghadami, M | 1 |
| Choe, PG; Choi, SJ; Kang, CK; Kim, NJ; Kim, TS; Oh, MD; Park, WB; Seong, MW; Song, SH | 1 |
| Darazam, IA; Golmohammadi, M; Irvani, SSN; Pourhoseingholi, MA; Shokouhi, S | 1 |
| Chen, K; Couban, RJ; Du, X; Gong, X; Guyatt, G; He, N; Ibrahim, QI; Li, X; Li, Y; Liu, F; Liu, J; Liu, W; Shen, N; Tang, Q; Wu, Z; Xu, X; Ye, Z; Ying, Y; Zhai, S; Zhang, Q; Zhang, Y; Zhou, P | 1 |
| Campos, L; Gouveia, CC | 1 |
| Danion, F; Fourtage, M; Greigert, V; Hansmann, Y; Kaeuffer, C; Lefebvre, N; Muller, J; Nai, T; Ruch, Y | 1 |
| Di Perri, G | 1 |
| Alonso-Herreros, JM; Berisa-Prado, S; Cañete-Ramírez, C; Dávila-Pousa, C; Flox-Benítez, MDP; Ladrón de Guevara-García, M; López-Cabezas, C; Martín de Rosales-Cabrera, AM; Ramos-Martínez, B | 1 |
| Choe, JY; Hong, HL; Jung, CY; Kim, EJ; Kim, JW; Kim, KC; Kwon, HH | 1 |
| Rockstroh, JK; Waters, L | 1 |
| Bae, IG; Cho, OH; Chong, YP; Hong, KW; Hong, SI; Kim, HC; Kim, S; Lee, S; Ryu, BH | 1 |
| Abedini, A; Baghaei, P; Dastan, F; Hashemian, SM; Jamaati, H; Marjani, M; Moniri, A; Nadji, SA; Saffaei, A; Tabarsi, P; Varahram, M; Yousefian, S | 1 |
| Chee, YJ; Tan, SK; Yeoh, E | 1 |
| Azadi, H; Darabi, E; Fathi, S; Ghanei, M; Ghazale, AH; Ghazvini, A; Izadi, M; Jafari, R; Movaseghi, F; Mozafari, A; Panahi, Y; Parsaei, MR; Ranjkesh, MH; Rezapour, M; Saadat, SH; Salesi, M; Vahedi, E; Zand, N | 1 |
| Bernasconi, E; Bertoli, R; Cerny, A; Ceschi, A; De Gottardi, A; Fratila, C; Gianella, P; Magenta, L; Majno-Hurst, P; Vanini, G | 1 |
| Magro, G | 1 |
| Gafarova, AR; Gainullina, EN; Timerbulatov, SV; Timerbulatov, VM; Timerbulstov, MV | 1 |
| Cemillán-Fernández, CA; Domingo-García, J; Fouz-Ruiz, D; Gómez-Enjuto, S; Hernando-Requejo, V; Lapeña-Motilva, J; Ogando-Durán, G; Rodríguez-García, E | 1 |
| Fueyo-Rodriguez, O; Moreno-Sanchez, F; Palomar-Lever, A; Valente-Acosta, B | 1 |
| Li, C; Ren, L; Wang, L | 1 |
| Bernal-Bello, D; Canalejo-Castrillero, E; Duarte-Millán, MÁ; Farfán-Sedano, AI; Frutos-Pérez, B; García de Viedma-García, V; Llarena-Barroso, C; Morales-Ortega, A; Ruiz-Giardín, JM; Ruiz-Ruiz, J; San Martín-López, JV | 1 |
| Aguado, P; Balsa, A; Bernad-Pineda, M; Bogas, P; Bonilla, G; Castilla-Plaza, A; De Miguel, E; Franco-Gómez, K; García-Lorenzo, E; Miranda-Carus, ME; Monjo, I; Novella Navarro, M; Nuño, L; Peiteado, D; Rodríguez-Araya, T; Tornero, C; Villalba, A | 1 |
| Fenioux, C; Funck-Brentano, C; Gligorov, J; Gougis, P; Solas, C; Spano, JP; Veyri, M | 1 |
| Carron, J; Hussein, H; Kennedy, M; McAdam, B; Sharif, Z; Sheahan, R | 1 |
| Baek, JH; Im, JH; Kwon, HY; Lee, JS; Nahm, CH | 1 |
| Martinez, MA | 1 |
| Baettig, V; Bassetti, S; Battegay, M; Egli, A; Franzeck, F; Gebhard, CE; Geenen, J; Hirsch, HH; Hollinger, A; Khanna, N; Marzolini, C; Mueller, D; Osthoff, M; Sendi, P; Stader, F; Stoeckle, M; Tschudin-Sutter, S; Weisser, M | 1 |
| Cauda, R; Cingolani, A; Cipriani, MC; Fantoni, M; Gremese, E; Larosa, L; Liperoti, R; Montemurro, G; Murri, R; Pasciuto, G; Pirronti, T; Tummolo, AM | 1 |
| Cleland, E; Giovane, RA; Henderson, CE; Rezai, S | 1 |
| Arzoine, J; Beurton, A; Boutolleau, D; Bureau, C; Burrel, S; Clarac, U; Clovet, O; De Sarcus, M; Decavele, M; Delemazure, J; Deleris, R; Demoule, A; Dres, M; Duceau, B; Faure, M; Grisot, PH; Haudebourg, L; Le Marec, J; Lecronier, M; Mayaux, J; Mora, P; Morawiec, E; Nemlaghi, S; Pari, MH; Raux, M; Virolle, S | 1 |
| Abbasian, L; Davoudi-Monfared, E; Hajiabdolbaghi, M; Kazemzadeh, H; Khalili, H; Rahmani, H; Salehi, M; Yekaninejad, MS | 1 |
| Bowen, A; Davis, J; Denholm, JT; Morpeth, S; O'Sullivan, M; Paterson, D; Price, D; Rees, M; Roberts, J; Snelling, T; Tong, SYC; Zentner, D | 1 |
| Manteuffel, J; Patel, HK; Ramesh, M; Spadaccini, M; Thoguluva Chandrasekar, V; Venkatesalu, B | 1 |
| Li, Z; Liu, Y; Wang, D | 1 |
| Álvarez, ED; Castro, CÁ; Morales, CM; Robles, AL; Sandoval, TP; Santos, CS | 1 |
| Cao, J; Fan, L; He, F; Hu, K; Lei, M; Luo, Q; Qin, S; Shao, X; Yang, L; Yu, N | 1 |
| Argov, Z; Gotkine, M; Haham, N; Orenbuch-Harroch, E; Rein, N; Romain, M; Vaknin-Dembinsky, A | 1 |
| Agarwal, A; Agoritsas, T; Azab, M; Bartoszko, JJ; Bravo, G; Brignardello-Petersen, R; Chu, DK; Couban, R; Devji, T; Escamilla, Z; Foroutan, F; Gao, Y; Ge, L; Ghadimi, M; Guyatt, GH; Han, MA; Heels-Ansdell, D; Honarmand, K; Hou, L; Ibrahim, Q; Izcovich, A; Khamis, A; Kum, E; Lam, B; Lamontagne, F; Loeb, M; Mansilla, C; Marcucci, M; Martinez, JPD; McLeod, SL; Miroshnychenko, A; Motaghi, S; Murthy, S; Mustafa, RA; Pardo-Hernandez, H; Qasim, A; Rada, G; Rizwan, Y; Saadat, P; Siemieniuk, RA; Switzer, C; Thabane, L; Tomlinson, G; Vandvik, PO; Vernooij, RW; Viteri-García, A; Wang, Y; Yao, L; Zeraatkar, D; Zhao, Y | 1 |
| Airó, P; Andreoli, L; Bertasi, V; Bianchi, M; Bottone, D; Brucato, A; Civelli, P; Colombo, E; Cotelli, MS; Damiolini, E; Franceschini, F; Furloni, R; Galbassini, G; Gatta, D; Ghirardelli, ML; Magri, R; Malamani, P; Mendeni, M; Miclini, M; Molinari, S; Morotti, A; Piantoni, S; Richini, D; Salada, L; Scarsi, M; Tincani, A; Turla, M; Vender, A | 1 |
| Barbonetti, A; Berardicurti, A; Berardicurti, O; D'Andrea, S; Felzani, G; Francavilla, F; Francavilla, S; Giacomelli, R | 1 |
| Gan, W; Gu, J; Li, H; Li, Y; Lu, C; Luo, P; Miao, H; Tian, M; Wang, J; Wang, S; Wu, M; Yao, Y; Yuan, B; Zhao, D; Zhao, X | 1 |
| Balerdi-Sarasola, L; Gainzarain-Arana, JC; Ganchegui-Aguirre, M; Molina-Iturritza, E; Ortiz-de-Zárate-Ibarra, Z; Portu-Zapirain, J; San-José-Muñiz, I | 1 |
| Barba-Gyengo, N; Cabrero-Rodríguez, C; Fernández-García, MÁ; Gámez-Baeza, P; Gámiz-Molina, AB; García-Martín, M; Guirado-Ruiz, PA; Jiménez-Mejías, E; Láinez-Ramos-Bossini, AJ; Mancera-Romero, J; Martín-delosReyes, LM; Martín-Romero, DT; Martínez-Diz, S; Martínez-Ruiz, V; R-delAmo, JL; Rivera-Izquierdo, M; Rodríguez-Camacho, M; Sánchez-Pérez, MR; Tahery-Mahmoud, A; Valero-Ubierna, MDC | 1 |
| Baumgartner, S; Ely, S; Jilma, B; Karolyi, M; Kelani, H; Laferl, H; Mader, T; Omid, S; Ott, C; Pawelka, E; Seitz, T; Traugott, M; Turner, M; Wenisch, C; Zoufaly, A | 1 |
| Antinori, S; Bassoli, C; Bradanini, L; Casalini, G; Cattaneo, D; Ceriani, E; Cogliati, C; Colombo, R; Conti, F; Galli, M; Gervasoni, C; Giacomelli, A; Morena, V; Oreni, L; Pagani, G; Passerini, S; Pezzati, L; Ridolfo, AL; Rizzardini, G; Rusconi, S | 1 |
| Ijaz, M; Khan, M; Kharaba, ZJ; Murtaza, G; Shamim, S | 1 |
| Burgos-Blasco, B; Donate-Lopez, J; Garcia-Feijoo, J; Güemes-Villahoz, N; Vidal-Villegas, B | 1 |
| Álvaro-Gracia, J; Castrejón, I; González, T; Martínez-Barrio, J; Molina Collada, J; Montero, F; Rivera, J; Serrano-Benavente, B | 1 |
| Alvaro-Gracia, JM; Blanco, R; Carmona, L; Castrejón, I; Fernández Fernández, D; Fernandez-Nebro, A; Galindo, M; Gonzalez-Gay, MA; Lledó, A; Manrique-Arija, S; Martinez-Lopez, D; Mena Vázquez, N; Mera-Varela, A; Pablos, JL; Retuerto, M | 1 |
| Barletta, JF; Burry, LD; Christian, MD; Dichter, J; Erstad, BL; Geiling, J; Kanji, S; Maves, RC; Williamson, D | 1 |
| Cameli, M; Cameli, P; Franchi, F; Mandoli, GE; Menci, D; Mondillo, S; Sciaccaluga, C; Sisti, N; Valente, S | 1 |
| Balzarini, L; Ferrozzi, F; Mancini, C; Marvisi, M; Ramponi, S; Uccelli, M | 1 |
| Ahmadinejad, Z; Ghiasvand, F; Golestan, FS; Hajiabdolbaghi, M; Jafari, F; Jafari, S; Jamalimoghadamsiahkali, S; Khalili, H; Kouchak, HE; Manafi, N; Pirhayati, M; Sadr, S; Salehi, M; Seifi, A; Sekhavati, E; SeyedAlinaghi, S; Tabarestani, M; Zendehdel, A | 1 |
| Ding, C; García, JA; García-Abellán, J; García-Pachón, E; Guillén, L; Gutiérrez, F; Masiá, M; Mora, A; Padilla, S; Telenti, G | 1 |
| Amézaga Menéndez, R; Catalán González, M; Díaz, E; Escapa, MG; Marcos Neira, P; Quintana Díaz, M; Serrano Lázaro, A; Suberviola, B; Vidal Cortés, P | 1 |
| Akarsu-Ayazoglu, T; Arslan, F; Aydin, O; Bas, G; Baysal, NB; Bektas, B; Cag, Y; Caskurlu, H; Ergen, P; Icten, S; Isik-Goren, B; Kalcioglu, MT; Kocoglu, H; Nural-Pamukcu, M; Selvi, E; Ucisik, AC; Uzman, S; Vahaboglu, H; Yilmaz-Karadag, F | 1 |
| Filipova, E; Pavlova, V; Uzunova, K; Vekov, T | 1 |
| Catino, A; Galetta, D; Longo, V; Montrone, M; Palmieri, VO | 1 |
| Birlutiu, V; Iancu, GM; Solomon, A | 1 |
| de Victoria Fernández, B; González Sánchez, IC; Redondo-Sendino, Á | 1 |
| Akahoshi, T; Iwasaka, S; Maki, J; Nagasaki, Y; Nakashima, K; Shimono, N; Shono, Y; Taguchi, T; Tokuda, K; Yamamoto, Y | 1 |
| Chang, MC; Hur, J; Lee, W; Park, D | 1 |
| Antonijević Miljaković, E; Antonijević, B; Baralić, K; Buha Djordjevic, A; Ćurčić, M; Jorgovanović, D; Živančević, K; Đukić-Ćosić, D | 1 |
| Becker, DP; Burns, MB; Durvasula, R; Gupta, Y; Idrissi, SZE; Kempaiah, P; Maciorowski, D; Medernach, BJ | 1 |
| Jones, CW; Platts-Mills, TF; Woodford, AL | 1 |
| Ader, F | 2 |
| Deng, M; Hu, Y; Jiang, L; Luo, X; Pan, L; Wang, M; Wu, T; Xia, Z; Yang, X; You, Y; Zuo, Z | 1 |
| Grundmark, B; Vidlin, SH; Watson, S; Zekarias, A | 1 |
| Arevalo-Serrano, J; Garcia-Gomez, C; Jimenez-Vizuete, JM; Martinez-Alfaro, E; Rodriguez-Garcia, JL; Sanchez-Nievas, G | 1 |
| Bodini, FC; Cavanna, L; Colombi, D; Michieletti, E; Milanese, G; Morelli, N; Silva, M | 1 |
| Mamishi, S; Navaeian, A; Shabanian, R | 1 |
| Baroutjian, A; Boneva, D; Elkbuli, A; McKenney, M; Sanchez, C | 1 |
| Gao, C; Jin, CC; Tong, YX; Xiao, AT; Zhang, S; Zhu, L | 1 |
| Fylaki, E; Hassapopoulou-Matamis, H; Mentis, A; Politis, C; Vlachogianni, G | 1 |
| Amparore, D; Checcucci, E; Dasgupta, P; Elhage, O; Fiori, C; Kotecha, P; Light, A; Porpiglia, F | 1 |
| Degboe, Y; Garcia, P; Montastruc, F; Revet, A; Rousseau, V; Yrondi, A | 1 |
| Bahurupi, YA; Bandyopadhyay, A; Chikara, G; Moirangthem, B; Panda, PK; Saha, S; Singh, BC | 1 |
| Cheong, HJ; Choi, MJ; Jung, J; Kang, M; Kim, WJ; Noh, JY; Shin, SY; Song, JY | 1 |
| Antinori, S; Bradanini, L; Cattaneo, D; Covizzi, A; Gervasoni, C; Giacomelli, A; Maggioni, AP; Oreni, L; Pasina, L; Ridolfo, A; Schiuma, M | 1 |
| Akat, H; Laloglu, F; Orbak, Z | 1 |
| Emani, SR; Emani, VR; Goswami, S; Nandanoor, D; Reddy, NK; Reddy, R | 1 |
| Arbustini, E; Bergomi, P; Bozzini, S; Cavagna, L; Colombo, R; Corsico, AG; Cova, E; D'Amato, M; Di Toro, A; Fossali, T; Frangipane, V; Lettieri, S; Lilleri, D; Meloni, F; Mojoli, F; Morosini, M; Ottolina, D; Pandolfi, L; Percivalle, E; Saracino, L; Tomaselli, S; Urtis, M | 1 |
| Bianco, G; Boari, GEM; Bonetti, S; Bonzi, B; Braglia-Orlandini, F; Chiarini, G; Desenzani, P; Faustini, C; Ferrari-Toninelli, G; Guarinoni, V; Malerba, P; Mascadri, C; Nardin, M; Pasini, G; Rizzoni, D; Saottini, M; Turini, D; Tusi, C; Viola, S; Zanotti, E | 1 |
| Abtahian, Z; Barati, S; Dastan, A; Dastan, F; Eskandari, R; Haseli, S; Jamaati, H; Marjani, M; Moniri, A; Monjazebi, F; Saffaei, A; Tabarsi, P; Vahedi, A; Yousefian, S | 1 |
| Aureau, I; Bernard, N; Bonnet, F; Bouchet, S; Contis, A; Hessamfar, M; Lahouati, M; Lapoirie, J; Meriglier, E; Pedeboscq, S; Rivoisy, C; Sacher, F; Sacristan, B; Vandenhende, MA | 1 |
| Belmas, AS; Danion, F; Fourtage, M; Gourieux, B; Michel, B; Nai, T; Nivoix, Y; Reisz, F; Reiter-Schatz, A; Ruch, Y; Walther, J | 1 |
| Mishra, SK; Tripathi, T | 1 |
| Amor-Garcia, MA; Bouza, E; Chamorro-de-Vega, E; Escudero-Vilaplana, V; Gimenez-Manzorro, A; Herranz, A; Machado, M; Manrique-Rodriguez, S; Melgarejo-Ortuño, A; Muñoz, P; Narrillos-Moraza, A; Olmedo, M; Rodriguez-Gonzalez, CG; Sancho-Gonzalez, M; Sanjurjo, M; Tejerina, F; Torroba-Sanz, B; Valerio, M; Vicente-Valor, J; Villanueva-Bueno, C | 1 |
| Abdool Karim, Q; Abi Hanna, P; Ader, F; Al-Bader, AM; Alejandria, MM; Alhasawi, A; Allum, E; Alotaibi, A; Alvarez-Moreno, CA; Appadoo, S; Asiri, A; Aukrust, P; Barratt-Due, A; Bellani, S; Branca, M; Cappel-Porter, HBC; Cerrato, N; Chow, TS; Como, N; Eustace, J; García, PJ; Godbole, S; Gotuzzo, E; Griskevicius, L; Hamra, R; Hassan, M; Hassany, M; Henao-Restrepo, AM; Hernández García, C; Hutton, D; Irmansyah, I; Jancoriene, L; Kieny, MP; Kirwan, J; Kumar, S; Lennon, P; Lopardo, G; Lydon, P; Magrini, N; Maguire, T; Malekzadeh, R; Manevska, S; Manuel, O; McGinty, S; Medina, MT; Mesa Rubio, ML; Miranda-Montoya, MC; Murthy, S; Nel, J; Nunes, EP; Pan, H; Perola, M; Peto, R; Portolés, A; Preziosi, MP; Rasmin, MR; Raza, A; Reddy, KS; Rees, H; Reges, PPS; Rogers, CA; Roses Periago, M; Røttingen, JA; Salami, K; Salvadori, MI; Sathiyamoorthy, V; Sinani, N; Sterne, JAC; Stevanovikj, M; Swaminathan, S; Tacconelli, E; Tikkinen, KAO; Trelle, S; Zaid, H | 1 |
| Albreem, MA; Alomari, OA; Alsharif, MH; Alsharif, YH; Hossain, MS; Jahid, A; Solyman, AAA; Yahya, K | 1 |
| Govil, A; Luckett, K; Miller-Handley, H | 1 |
| Haddad, F; Herth, FJF; Sakoulas, G | 1 |
| Dehghan, N; Keyvani, H; Laali, A; Makiani, MJ; Navaei, M; Nojomi, M; Ranjbar, M; Roham, M; Yassin, Z | 1 |
| Gao, Q; Liu, D; Ma, D; Song, C; Tan, J; Xu, C; Yuan, Y | 1 |
| Kumar, D; Trivedi, N; Verma, A | 1 |
| Daniel, NM; Hilden, P; Raja, K; Smoke, SM | 1 |
| Dingding, Q; Jiangfang, L; Yujia, W; Zequn, Z | 1 |
| Álvarez-Payero, M; Casanova-Martínez, C; Castro-Núñez, I; García-Beloso, N; González-Costas, S; Inaraja-Bobo, MT; Leboreiro-Enríquez, B; López-López, A; Lorenzo-Lorenzo, K; Martínez-López-de-Castro, N; Martínez-Reglero, C; Otero-Millán, L; Paradela-Carreiro, A; Pérez-Landeiro, A; Piñeiro-Corrales, G; Regueira-Arcay, AM; Robles-Torres, D; Samartín-Ucha, M; Vázquez-López, C; Yaiza Romero-Ventosa, E | 1 |
| Amedeo, A; Beci, G; Calza, L; Cipolli, M; Cucchetto, G; Giglia, M; Guardigni, V; Rosselli Del Turco, E; Verucchi, G; Viale, P | 1 |
| Agoritsas, T; Baggio, S; Calmy, A; Gayet-Ageron, A; Gold, G; Perrier, A; Picard, F; Prendki, V; Reny, JL; Samer, C; Stirnemann, J; Vernaz, N; Vetter, P; Zanella, MC; Zekry, D | 1 |
| Bartoletti, M; Gaibani, P; Ranieri, VM; Re, MC; Tonetti, T; Viale, P | 1 |
| Dadvand, H; Davoodian, P; Fathalipour, M; Ghazizadeh, S; Hassaniazad, M; Hassanipour, S; Hosseini, FS; Kahoori, S; Malektojari, A; Nikoofal-Sahlabadi, S; Nikpoor, AR; Sepandi, M | 1 |
| Chen, J; Liu, D; Lu, H; Yin, L; Zhang, L | 1 |
| Mokale, SN; More, SA; Patil, AS; Sakle, NS | 1 |
| Wen, S; Xu, X; Yadav, AK; Yu, L | 1 |
| Keestra, S; Pepperrell, T; Pilkington, V; Rodgers, F | 1 |
| Dehghan, H; Fazlzadeh, A; Haddad, F; Kheirabadi, D; Mousavi-Roknabadi, RS; Rezaeisadrabadi, M | 1 |
| Auricchio, A; Celletti, E; Cipollone, F; Di Nicola, M; Di Penta, M; Falasca, K; Marchioni, M; Sabatini, E; Ucciferri, C; Vecchiet, J | 1 |
| Alhashmi, A; Belfaqeeh, O; Janapala, RN; Patel, J; Pourmand, A | 1 |
| Mylonakis, E; Zhang, R | 1 |
| Aalipour, MA; Darazam, IA; Ghorbani, F; Pakdaman, H; Ramezani, M; Sagharichi, M; Simani, L | 1 |
| Brügel, M; Habler, K; Liebchen, U; Paal, M; Scharf, C; Schönermarck, U; Teupser, D; Vogeser, M | 1 |
| Berkman, SA; Tapson, VF | 1 |
| Danduga, RCSR; James, RA; Kandaswamy, DK; Raj, CTD; Rajasabapathy, R | 1 |
| Abbasian, L; Dehghan Manshadi, SA; Ghaderkhani, S; Ghiasvand, F; Hasannezhad, M; Jafari, F; JamaliMoghadamSiahkali, S; Koolaji, S; Manafi, N; Meidani, M; Salahshour, F; Salehi, M; Sekhavati Moghadam, E; SeyedAlinaghi, S; Tabarestani, M; Zarezade, B; Zendehdel, A | 1 |
| Afrooz, N; Aminimoghaddam, S; Mahmoudzadeh, F; Motaghi Nejad, O; Nasiri, S | 1 |
| Amato, L; Cruciani, F; Davoli, M; De Crescenzo, F; Mitrova, Z; Saulle, R; Vecchi, S | 1 |
| Alotaibi, NH; Bokharee, N; Khan, YH; Khokhar, A; Mallhi, TH; Rasheed, M | 1 |
| Gullón, P; Lara, MÁ; Obispo, B; Rogado, J; Serrano, G | 1 |
| Andy Ko, TY; Chen, LS; Koh, KT; Ling, HS; Pang, IX; Sia Tonnii, LL; Wong, TC | 1 |
| Abdulai, SI; Adewole, KE; Asogwa, NT; Ishola, AA; Tijjani, H | 1 |
| Brañez-Condorena, A; Diaz-Arocutipa, C; Hernandez, AV | 1 |
| Bonnabry, P; Eggimann, F; Grauser, D; Grosgurin, O; Guignard, B; Reny, JL; Samer, C; Skalafouris, C; Stirnemann, J | 1 |
| Figueiredo Neto, AD; Forrest, JI; Guimarães de Almeida, APF; Harari, O; Medeiros Silva, DC; Milagres, AC; Mills, EJ; Moreira Silva, EADS; Oliveira, R; Park, JJH; Quirino Dos Santos, CV; Reis, G; Ribeiro, LB; Savassi, LCM; Simplicio, MIC; Singh, G; Teixeira, MM; Thabane, L | 1 |
| Demiri, I; Dimkovski, A; Dimovski, A; Filipce, V; Grozdanova, A; Panovska-Stavridis, I; Ridova, N; Ristevska, T; Stevanovic, M; Stojanoska, T; Stojanovska, S | 1 |
| Angkasekwinai, N; Assanasen, S; Chayakulkeeree, M; Chierakul, N; Horthongkham, N; Jitmuang, A; Kantakamalakul, W; Koomanachai, P; Ratanarat, R; Rattanaumpawan, P; Rongrungruang, Y; Sirijatuphat, R; Suputtamongkol, Y; Wangchinda, W | 1 |
| Anedda, L; Bianchini, L; Cuzzolin, L; Fanos, V; Finco, G; Marcialis, MA | 1 |
| Bellavita, G; Bonzi, L; Buoite Stella, A; Cecotti, L; D Acunto, L; Fabris, M; Furlanis, G; Manganotti, P; Pesavento, V; Sartori, A; Tommasini, V | 1 |
| Bassetti, M; Corcione, S; De Rosa, FG; Dettori, S; Giacobbe, DR; Gori, A; Lombardi, A; Lupia, T; Vena, A | 1 |
| Biever, PM; Hornuss, D; Jaenigen, B; Kern, WV; Rieg, S; Schneider, J; Wagner, D; Walz, G | 1 |
| Ahmed, WU; Alghoul, H; Alser, O; Alshammari, TM; Areia, C; Burn, E; Carter, W; Casajust, P; Cho, J; Dawoud, D; Duarte-Salles, T; Golozar, A; Gong, M; Hripcsak, G; Jonnagaddala, J; Kostka, K; Lai, LYH; Lane, JC; Liu, L; Lynch, KE; Matheny, ME; Mehta, PP; Morales, DR; Nyberg, F; Posada, JD; Prats-Uribe, A; Prieto-Alhambra, D; Recalde, M; Reich, C; Rijnbeek, PR; Roel, E; Ryan, PB; Schilling, LM; Sena, AG; Shah, K; Shah, NH; Subbian, V; Suchard, MA; Vizcaya, D; You, SC; Zhang, L; Zhang, Y; Zhu, H | 1 |
| Chandra, PP; Jain, S; Potschka, H; Tripathi, M; Vohora, D | 1 |
| Amani, B; Hashemi, P; Khanijahani, A | 1 |
| Ader, F; Alfaiate, T; Andrejak, C; Belhadi, D; Botelho-Nevers, E; Bouadma, L; Bouiller, K; Bouscambert-Duchamp, M; Burdet, C; Cabié, A; Clere-Jehl, R; Costagliola, D; Courjon, J; Danion, F; Dechanet, A; Delmas, C; Diallo, A; Dubost, C; Dupont, A; Epaulard, O; Faure, E; Gaci, R; Gagneux-Brunon, A; Gallien, S; Goehringer, F; Hites, M; Jaureguiberry, S; Kimmoun, A; Lacombe, K; Lanoix, JP; Launay, O; Lê, MP; Leroy, S; Lescure, FX; Lina, B; Makinson, A; Martin-Blondel, G; Mentré, F; Mercier, N; Mootien, J; Mourvillier, B; Navellou, JC; Noret, M; Nseir, S; Peiffer-Smadja, N; Peytavin, G; Piroth, L; Poissy, J; Pourcher, V; Raffi, F; Reignier, J; Reuter, J; Richard, JC; Saillard, J; Staub, T; Tolsma, V; Wallet, F; Yazdanpanah, Y | 1 |
| Cantudo-Cuenca, MD; Contreras-Macías, E; Fernández-Fuertes, M; Gutiérrez-Pizarraya, A; Lao-Domínguez, FA; Macías, J; Morillo-Verdugo, R; Pineda, JA; Pinilla-Fernández, A; Rincón, P | 1 |
| Benito-González, T; Borrego-Rodríguez, J; Del Castillo-García, S; Echarte-Morales, J; Fernández-Vázquez, F; Flores-Vergara, G; García-Bergel, R; Iglesias-Garriz, I; Maniega, CG; Menéndez-Suárez, P; Minguito-Carazo, C; Palacios-Echavarren, C; Prieto-González, S; Rodríguez-Santamarta, M; Sánchez-Muñoz, E | 1 |
| Kawano-Dourado, L; Qadir, N; Rochwerg, B | 1 |
| Angus, DC; Annane, D; Arabi, YM; Beane, A; Beasley, R; Beidh, FA; Berry, LR; Berry, S; Bhimani, Z; Bonten, MJM; Bradbury, CA; Brunkhorst, FM; Buxton, M; Buzgau, A; Cheng, A; De Jong, M; Derde, LPG; Detry, MA; Duffy, EJ; Estcourt, LJ; Fitzgerald, M; Fowler, R; Girard, TD; Goligher, EC; Goossens, H; Gordon, AC; Green, C; Haniffa, R; Higgins, AM; Hills, TE; Horvat, CM; Huang, DT; King, AJ; Lamontagne, F; Lawler, PR; Lewis, R; Linstrum, K; Litton, E; Lorenzi, E; Malakouti, S; Marshall, JC; McArthur, C; McAuley, DF; McGlothlin, A; Mcguinness, S; McVerry, BJ; Montgomery, SK; Morpeth, SC; Mouncey, PR; Murthy, S; Nichol, AD; Orr, K; Parke, R; Parker, JC; Patanwala, AE; Rowan, KM; Santos, MS; Saunders, CT; Seymour, CW; Shankar-Hari, M; Swaidan, LA; Tong, SYC; Turgeon, AF; Turner, AM; Van de Veerdonk, FL; Webb, SA; Zarychanski, R | 1 |
| Alimohamadi, Y; Fard, SR; Kalantari, S; Maleki, D; Minaeian, S; Taher, MT; Yassin, Z | 1 |
| Bao, Y; Chen, Z; Ding, J; Feng, Y; Guan, H; Li, H; Liu, W; Wang, X; Zhou, Z | 1 |
| Alavi Darazam, I; Amirdosara, M; Dehbsneh, HS; Gachkar, L; Gharehbagh, FJ; Hajiesmaeili, M; Hatami, F; Irvani, SSN; Khalili, N; Khoshkar, A; Kusha, AH; Lotfollahi, L; Mardani, M; Moradi, O; Pourhoseingholi, MA; Rabiei, MM; Rezaei, O; Shabani, M; Shokouhi, S; Shoushtari, MT; Soleymaninia, A; Torabinavid, P | 1 |
| Arabi, M; Bitar, F; Eid, AH; Fakhri, G; Younis, NK; Zareef, RO | 1 |
| Alkan, M; Demirkol, MA; Dinc, V; Esatoglu, SN; Kamat, S; Kostek, ME; Sargin Altunok, E; Satici, C; Toprak, ID; Yazla, S | 1 |
| Angela, M; Ardhany, AR; Febriane, E; Hertanto, DM; Mardiana, N; Muliono, AC; Pramudya, D; Santoso, D; Setiawan, P; Sugiarto, D; Suryantoro, SD; Tanuwidjaja, H; Thaha, M; Tjempakasari, A | 1 |
| Choudhury, M; Dhanabalan, AK; Goswami, N | 1 |
| Cevenini, F; Fallani, E; Lazzerini, PE; Saponara, S; Verdini, A | 1 |
| Abayomi, A; Abdur-Razzaq, H; Anya, SE; Erinoso, OA; Ezechi, O; Kuyinu, Y; Ojo, O; Ola, B; Osibogun, A; Wright, K; Zamba, E | 1 |
| Abdi, A; Bavand, A; Farahani, E; Mazaherpour, H; Mazaherpour, S; Ramezani, A; Sofian, M | 1 |
| Bhardwaj, M; Chiu, MN; Sah, SP | 1 |
| Agoritsas, T; Bartoszko, JJ; Brignardello-Petersen, R; Chu, DK; Ge, L; Izcovich, A; Khamis, AM; Kum, E; McLeod, SL; Mustafa, RA; Qasim, A; Rochwerg, B; Siemieniuk, RA; Vandvik, P; Zeraatkar, D | 1 |
| Anandaradje, A; George, M; Melepurakkal Sadanandan, D; Nair, NS; Selvarajan, S; Shivabasappa, S | 1 |
| Ioannidis, JPA | 1 |
| Dijk, SW; Gross, CP; Hunink, MGM; Krijkamp, EM; Kunst, N; Wong, JB | 1 |
| Hong, W; Hwang, TH; Jang, J; Jang, SP; Jang, SW; Kim, BO; Park, HW; Park, SK; Park, YK; Shin, J; Yang, W | 1 |
| Daly, G; Lurie, P; Moneer, O; Nyhan, K; Ross, JS; Skydel, JJ; Wallach, JD | 1 |
| Ballet, S; Caufriez, A; Cooreman, A; Dos Santos Rodrigues, B; Kadam, P; Lamouroux, A; Leroy, K; Sanz Serrano, J; Tabernilla, A; Van Campenhout, R; Vinken, M | 1 |
| Atal, S; Kaore, S | 1 |
| Akbal-Dagistan, O; Basarir, NS; Culha, M; Erturk, A; Sahin, G; Sancar, S; Yildiz-Pekoz, A | 1 |
| Alquézar-Arbé, A; Burillo-Putze, G; García-Lamberechts, EJ; González Del Castillo, J; Jacob, J; Jiménez, S; Llorens, P; Martín-Sánchez, FJ; Miró, Ò; Piñera, P | 1 |
| Bulgakova, VA; Chulanov, VP; Grekova, AI; Ivanova, AP; Kanshina, NN; Kareva, EN; Khasanova, GM; Kolaeva, NV; Kravchenko, IE; Leneva, IA; Malinin, OV; Nikolaeva, IV; Orlova, SN; Petrov, VA; Pshenichnaya, NY; Puzyreva, LV; Tikhonova, EP; Volchkova, EV | 1 |
| Al-Beidh, F; Angus, DC; Annane, D; Arabi, YM; Beane, A; Berry, LR; Berry, S; Bhimani, Z; Bonten, MJM; Bradbury, CA; Brunkhorst, FM; Burrell, A; Buxton, M; Buzgau, A; Charles, WN; Cove, M; Derde, LPG; Detry, MA; Estcourt, LJ; Fagbodun, EO; Fitzgerald, M; Girard, TD; Goligher, EC; Goossens, H; Gordon, AC; Green, C; Haniffa, R; Higgins, AM; Hills, T; Horvat, CM; Huang, DT; Ichihara, N; Lamontagne, F; Lawler, PR; Lewis, RJ; Lorenzi, E; Marshall, JC; McArthur, CJ; McAuley, DF; McGlothlin, A; McGuinness, SP; McQuilten, Z; McVerry, BJ; Mouncey, PR; Murthy, S; Neal, MD; Nichol, AD; Parke, RL; Parker, JC; Parry-Billings, K; Peters, SEC; Reyes, LF; Rowan, KM; Saito, H; Santos, MS; Saunders, CT; Serpa-Neto, A; Seymour, CW; Shankar-Hari, M; Stronach, LM; Turgeon, AF; Turner, AM; van Bentum-Puijk, W; van de Veerdonk, FL; Webb, SA; Zarychanski, R | 1 |
| Chiche, L; Coquet, E; Pegliasco, H; Peretti, M; Rebaudet, S | 1 |
63 review(s) available for hydroxychloroquine and lopinavir
| Article | Year |
|---|---|
Chinese Therapeutic Strategy for Fighting COVID-19 and Potential Small-Molecule Inhibitors against Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
Topics: Antiviral Agents; China; Coronavirus Protease Inhibitors; COVID-19; COVID-19 Drug Treatment; Drugs, Chinese Herbal; Humans; Medicine, Chinese Traditional; SARS-CoV-2; Small Molecule Libraries | 2020 |
The recent outbreaks of human coronaviruses: A medicinal chemistry perspective.
Topics: Antiviral Agents; Chemistry, Pharmaceutical; COVID-19; Disease Outbreaks; Drug Repositioning; Humans; Virus Internalization | 2021 |
Potential therapeutic agents against COVID-19: What we know so far.
Topics: Adenosine Monophosphate; Alanine; Betacoronavirus; Clinical Trials as Topic; Coronavirus Infections; COVID-19; Drug Combinations; Humans; Hydroxychloroquine; Interferon-alpha; Lopinavir; Pandemics; Pneumonia, Viral; Ritonavir; SARS-CoV-2 | 2020 |
Review of Emerging Pharmacotherapy for the Treatment of Coronavirus Disease 2019.
Topics: Adenosine Monophosphate; Adrenal Cortex Hormones; Alanine; Antibodies, Monoclonal, Humanized; Antiviral Agents; Azetidines; Betacoronavirus; Chloroquine; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; COVID-19 Serotherapy; Drug Combinations; Humans; Hydroxychloroquine; Immunization, Passive; Immunomodulation; Interferon-alpha; Lopinavir; Nelfinavir; Nitro Compounds; Pandemics; Pneumonia, Viral; Purines; Pyrazoles; Ribavirin; Ritonavir; SARS-CoV-2; Sulfonamides; Thiazoles | 2020 |
Pharmacologic Treatments for Coronavirus Disease 2019 (COVID-19): A Review.
Topics: Adenosine Monophosphate; Adrenal Cortex Hormones; Alanine; Amides; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Antiviral Agents; Azithromycin; Betacoronavirus; Chloroquine; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Humans; Hydroxychloroquine; Immunoglobulins; Immunologic Factors; Indoles; Lopinavir; Oseltamivir; Pandemics; Pneumonia, Viral; Pyrazines; Ribavirin; Ritonavir; SARS-CoV-2; Withholding Treatment | 2020 |
Antiviral treatment of COVID-19
Topics: Adenosine Monophosphate; Alanine; Amides; Antiviral Agents; Betacoronavirus; Chloroquine; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Drug Combinations; Humans; Hydroxychloroquine; Ivermectin; Lopinavir; Nitro Compounds; Pandemics; Pneumonia, Viral; Pyrazines; Ritonavir; SARS-CoV-2; Thiazoles | 2020 |
Treatment options for COVID-19: The reality and challenges.
Topics: Adenosine Monophosphate; Alanine; Amides; Antiviral Agents; Azithromycin; Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Serotherapy; Drug Combinations; Humans; Hydroxychloroquine; Immunization, Passive; Lopinavir; Pandemics; Pneumonia, Viral; Pyrazines; Ritonavir; RNA-Dependent RNA Polymerase; SARS-CoV-2; Teicoplanin | 2020 |
Respiratory Support in COVID-19 Patients, with a Focus on Resource-Limited Settings.
Topics: Adenosine Monophosphate; Alanine; Betacoronavirus; Chloroquine; Continuous Positive Airway Pressure; Coronavirus Infections; COVID-19; Developing Countries; Disease Management; Humans; Hydroxychloroquine; Lopinavir; Lung; Oxygen; Pandemics; Pneumonia, Viral; Respiration, Artificial; Ritonavir; SARS-CoV-2; Tomography, X-Ray Computed | 2020 |
Treatment of SARS-CoV-2: How far have we reached?
Topics: Adenosine Monophosphate; Alanine; Amides; Antibodies, Monoclonal, Humanized; Antiviral Agents; Betacoronavirus; Chloroquine; Clinical Trials as Topic; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; COVID-19 Serotherapy; Darunavir; Drug Combinations; Humans; Hydroxychloroquine; Immunization, Passive; Indoles; Interferon-alpha; Interferon-beta; Lopinavir; Pandemics; Pneumonia, Viral; Pyrazines; Ritonavir; SARS-CoV-2 | 2020 |
COVID-19 in Children: Clinical Approach and Management.
Topics: Acute Lung Injury; Antiviral Agents; Betacoronavirus; Child; Child, Preschool; Clinical Laboratory Techniques; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; COVID-19 Testing; Disease Outbreaks; Humans; Hydroxychloroquine; Infant; Lopinavir; Palliative Care; Pandemics; Pneumonia, Viral; Protease Inhibitors; Respiratory Distress Syndrome; Reverse Transcriptase Polymerase Chain Reaction; Ritonavir; SARS-CoV-2; Severe Acute Respiratory Syndrome | 2020 |
Addressing the Impact of the Coronavirus Disease 2019 (COVID-19) Pandemic on Hematopoietic Cell Transplantation: Learning Networks as a Means for Sharing Best Practices.
Topics: Adenosine Monophosphate; Alanine; Betacoronavirus; Bone Marrow Transplantation; Clinical Laboratory Techniques; Coronavirus Infections; COVID-19; COVID-19 Serotherapy; COVID-19 Testing; Drug Combinations; Education, Distance; Hematopoietic Stem Cell Transplantation; Humans; Hydroxychloroquine; Immunization, Passive; Infection Control; Information Dissemination; Lopinavir; Pandemics; Pneumonia, Viral; Practice Guidelines as Topic; Real-Time Polymerase Chain Reaction; Ritonavir; SARS-CoV-2; Severity of Illness Index; Tissue Donors | 2020 |
Medicines for the Treatment Of COVID-19: Awaiting the Evidence.
Topics: Adenosine Monophosphate; Alanine; Antibodies, Monoclonal, Humanized; Antiviral Agents; Betacoronavirus; Chloroquine; Coronavirus Infections; COVID-19; Drug Combinations; Drugs, Investigational; Global Health; Humans; Hydroxychloroquine; Lopinavir; Off-Label Use; Pandemics; Pneumonia, Viral; Ritonavir; SARS-CoV-2 | 2020 |
Cardiovascular Safety of Potential Drugs for the Treatment of Coronavirus Disease 2019.
Topics: Adenosine Monophosphate; Alanine; Anti-Infective Agents; Azithromycin; Betacoronavirus; Cardiovascular Diseases; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Drug Combinations; Enzyme Inhibitors; Humans; Hydroxychloroquine; Lopinavir; Pandemics; Pneumonia, Viral; Ritonavir; SARS-CoV-2 | 2020 |
A Guide to COVID-19: a global pandemic caused by the novel coronavirus SARS-CoV-2.
Topics: Adenosine Monophosphate; Alanine; Antiviral Agents; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; COVID-19 Testing; COVID-19 Vaccines; Drug Combinations; Humans; Hydroxychloroquine; Interferon beta-1a; Lopinavir; Middle East Respiratory Syndrome Coronavirus; Pandemics; Respiration, Artificial; Ritonavir; SARS-CoV-2; Severe Acute Respiratory Syndrome; Severe acute respiratory syndrome-related coronavirus; Severity of Illness Index | 2020 |
Efficacy and safety of antiviral treatment for COVID-19 from evidence in studies of SARS-CoV-2 and other acute viral infections: a systematic review and meta-analysis.
Topics: Amides; Antiviral Agents; Betacoronavirus; Chloroquine; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Evidence-Based Medicine; Humans; Hydroxychloroquine; Indoles; Influenza, Human; Lopinavir; Observational Studies as Topic; Pandemics; Pneumonia, Viral; Pyrazines; Ribavirin; Ritonavir; SARS-CoV-2 | 2020 |
Coronavirus Disease 2019: Clinical Review.
Topics: Adenosine Monophosphate; Alanine; Amides; Animals; Antiviral Agents; Azithromycin; Betacoronavirus; Blood Coagulation Disorders; China; Chiroptera; Chloroquine; Coronavirus Infections; COVID-19; Glucocorticoids; Humans; Hydroxychloroquine; Infectious Disease Incubation Period; Lopinavir; Lung; Pandemics; Pneumonia, Viral; Prognosis; Pyrazines; Radiography, Thoracic; Reverse Transcriptase Polymerase Chain Reaction; SARS-CoV-2; Symptom Assessment | 2020 |
Dissecting the interaction between COVID-19 and diabetes mellitus.
Topics: Antibodies, Monoclonal, Humanized; Antiviral Agents; Blood Glucose; Chloroquine; Comorbidity; COVID-19; COVID-19 Drug Treatment; COVID-19 Vaccines; Diabetes Complications; Diabetes Mellitus; Diabetic Ketoacidosis; Dipeptidyl-Peptidase IV Inhibitors; Drug Combinations; Glucagon-Like Peptide-1 Receptor; Glycemic Control; Humans; Hydroxychloroquine; Hypoglycemic Agents; Insulin; Insulin Resistance; Insulin Secretion; Interferon Type I; Lopinavir; Lung; Metformin; Obesity; Pancreas; Ritonavir; Severity of Illness Index; Sodium-Glucose Transporter 2 Inhibitors; Sulfonylurea Compounds; Thiazolidinediones | 2020 |
COVID-19: Review on latest available drugs and therapies against SARS-CoV-2. Coagulation and inflammation cross-talking.
Topics: Adenosine Monophosphate; Alanine; Anti-Inflammatory Agents; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibodies, Neutralizing; Anticoagulants; Antiviral Agents; Azetidines; Betacoronavirus; Coronavirus Infections; COVID-19; Cytokine Release Syndrome; Disseminated Intravascular Coagulation; Drug Combinations; Heparin; Humans; Hydroxychloroquine; Inflammation; Interleukin 1 Receptor Antagonist Protein; Lopinavir; Pandemics; Pneumonia, Viral; Purines; Pyrazoles; Ritonavir; SARS-CoV-2; Sulfonamides | 2020 |
[Drug treatment of coronavirus disease COVID-19: evidence exists?]
Topics: Adenosine Monophosphate; Alanine; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Betacoronavirus; Chloroquine; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; COVID-19 Serotherapy; Drug Combinations; Humans; Hydroxychloroquine; Immunization, Passive; Lopinavir; Pandemics; Pneumonia, Viral; Ritonavir; SARS-CoV-2; Tissue Plasminogen Activator | 2020 |
Antiviral mechanisms of candidate chemical medicines and traditional Chinese medicines for SARS-CoV-2 infection.
Topics: Adenosine Monophosphate; Alanine; Amides; Antiviral Agents; Betacoronavirus; China; Coronavirus Infections; COVID-19; Drug Combinations; Drugs, Chinese Herbal; Humans; Hydroxychloroquine; Indoles; Interferons; Lopinavir; Pandemics; Pneumonia, Viral; Pyrazines; Ribavirin; Ritonavir; SARS-CoV-2; Survival Analysis; Teicoplanin | 2020 |
Clinical guidance for navigating the QTc-prolonging and arrhythmogenic potential of pharmacotherapy during the COVID-19 pandemic.
Topics: Anti-Bacterial Agents; Antiviral Agents; Azithromycin; COVID-19 Drug Treatment; Drug Combinations; Electrocardiography; Enzyme Inhibitors; Humans; Hydroxychloroquine; Long QT Syndrome; Lopinavir; Magnesium; Pandemics; Potassium; Practice Guidelines as Topic; Risk Assessment; Risk Factors; Ritonavir; SARS-CoV-2; Torsades de Pointes | 2021 |
Clinical Trials of Repurposed Antivirals for SARS-CoV-2.
Topics: Adenosine Monophosphate; Alanine; Amides; Antiviral Agents; Betacoronavirus; Coronavirus Infections; COVID-19; Drug Administration Schedule; Drug Combinations; Drug Repositioning; Humans; Hydroxychloroquine; Interferons; Lopinavir; Pandemics; Pneumonia, Viral; Pyrazines; Randomized Controlled Trials as Topic; Ribavirin; Ritonavir; SARS-CoV-2; Survival Analysis; Treatment Outcome | 2020 |
Current pharmacological modalities for management of novel coronavirus disease 2019 (COVID-19) and the rationale for their utilization: A review.
Topics: Adenosine Monophosphate; Alanine; Angiotensin-Converting Enzyme 2; Antibodies, Monoclonal, Humanized; Antiviral Agents; Betacoronavirus; Coronavirus Infections; COVID-19; Disease Progression; Drug Combinations; Drug Repositioning; Esters; Gabexate; Gene Expression Regulation; Guanidines; Host-Pathogen Interactions; Humans; Hydroxychloroquine; Indoles; Lopinavir; Pandemics; Peptidyl-Dipeptidase A; Pneumonia, Viral; Ritonavir; SARS-CoV-2; Spike Glycoprotein, Coronavirus | 2020 |
Systematic review and meta-analysis of effectiveness of treatment options against SARS-CoV-2 infection.
Topics: Adenosine Monophosphate; Adrenal Cortex Hormones; Alanine; Antibodies, Monoclonal, Humanized; Antiviral Agents; COVID-19; COVID-19 Serotherapy; Drug Administration Schedule; Drug Combinations; Female; Humans; Hydroxychloroquine; Immunization, Passive; Lopinavir; Male; Middle Aged; Odds Ratio; Ritonavir; SARS-CoV-2; Survival Analysis; Treatment Outcome | 2021 |
An overview of the safety, clinical application and antiviral research of the COVID-19 therapeutics.
Topics: Adenosine Monophosphate; Alanine; Amides; Angiotensin-Converting Enzyme Inhibitors; Antimalarials; Antiviral Agents; Betacoronavirus; Biomedical Research; Coronavirus Infections; COVID-19; COVID-19 Serotherapy; Drug Combinations; Drug Development; Drugs, Chinese Herbal; Humans; Hydroxychloroquine; Immunization, Passive; Indoles; Interferons; Lopinavir; Pandemics; Pneumonia, Viral; Pyrazines; Ribavirin; Ritonavir; SARS-CoV-2 | 2020 |
Successful recovery of recurrence of positive SARS-CoV-2 RNA in COVID-19 patient with systemic lupus erythematosus: a case report and review.
Topics: Adult; Anti-Bacterial Agents; Antirheumatic Agents; Antiviral Agents; Betacoronavirus; Clinical Laboratory Techniques; Coronavirus Infections; COVID-19; COVID-19 Testing; Drug Combinations; Female; Glucocorticoids; Humans; Hydroxychloroquine; Immunosuppressive Agents; Lopinavir; Lung; Lupus Erythematosus, Systemic; Moxifloxacin; Mycophenolic Acid; Pandemics; Pneumonia, Viral; Prednisone; Recurrence; Reverse Transcriptase Polymerase Chain Reaction; Ritonavir; RNA, Viral; SARS-CoV-2; Tomography, X-Ray Computed | 2020 |
Drug treatments for covid-19: living systematic review and network meta-analysis
Topics: Adenosine Monophosphate; Alanine; Antiviral Agents; Betacoronavirus; Centers for Disease Control and Prevention, U.S.; China; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Databases, Factual; Drug Combinations; Evidence-Based Medicine; Glucocorticoids; Humans; Hydroxychloroquine; Lopinavir; Network Meta-Analysis; Pandemics; Pneumonia, Viral; Randomized Controlled Trials as Topic; Respiration, Artificial; Ritonavir; SARS-CoV-2; Severity of Illness Index; Standard of Care; Treatment Outcome; United States | 2020 |
Update on recommendations for the diagnosis and treatment of SARS-CoV-2 infection in children.
Topics: Adenosine Monophosphate; Alanine; Antiviral Agents; Asymptomatic Diseases; Betacoronavirus; Biomarkers; Child; Clinical Laboratory Techniques; Coronavirus Infections; Cough; COVID-19; COVID-19 Testing; Drug Combinations; Early Diagnosis; Fever; Humans; Hydroxychloroquine; Interferon-alpha; Lopinavir; Pandemics; Pneumonia, Viral; Practice Guidelines as Topic; Ribavirin; Ritonavir; RNA, Viral; SARS-CoV-2; Severity of Illness Index; Tomography, X-Ray Computed | 2020 |
Potential strategies for combating COVID-19.
Topics: Adenosine Monophosphate; Adrenal Cortex Hormones; Alanine; Amides; Antibodies, Monoclonal, Humanized; Antiviral Agents; Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Serotherapy; COVID-19 Vaccines; Cytokine Release Syndrome; Drug Combinations; Humans; Hydroxychloroquine; Immunization, Passive; Immunologic Factors; Indoles; Interleukin 1 Receptor Antagonist Protein; Lopinavir; Pandemics; Pneumonia, Viral; Pyrazines; Ritonavir; SARS-CoV-2; Severity of Illness Index; Viral Vaccines | 2020 |
It Takes a Village…: Contending With Drug Shortages During Disasters.
Topics: Antiviral Agents; COVID-19; Critical Care; Disasters; Drug Combinations; Drug Industry; Drug Repositioning; Humans; Hydroxychloroquine; Hypnotics and Sedatives; Internationality; Inventories, Hospital; Length of Stay; Lopinavir; Pharmaceutical Preparations; Respiration, Artificial; Ritonavir; Strategic Stockpile; Surge Capacity; United States; United States Food and Drug Administration | 2020 |
COVID-19 and the burning issue of drug interaction: never forget the ECG.
Topics: Adenosine Monophosphate; Alanine; Antibodies, Monoclonal, Humanized; Antirheumatic Agents; Antiviral Agents; Arrhythmias, Cardiac; Chloroquine; COVID-19 Drug Treatment; Drug Combinations; Drug Interactions; Electrocardiography; Heart Failure; Humans; Hydroxychloroquine; Hypoxia; Inflammation; Long QT Syndrome; Lopinavir; Myocarditis; Myocardium; Precipitating Factors; Receptors, Interleukin-6; Respiratory Distress Syndrome; Ribavirin; Ritonavir; SARS-CoV-2; Water-Electrolyte Imbalance | 2021 |
[Pharmacological treatment of COVID-19: Narrative review of the Working Group in Infectious Diseases and Sepsis (GTEIS) and the Working Groups in Transfusions and Blood Products (GTTH)].
Topics: Adenosine Monophosphate; Adrenal Cortex Hormones; Alanine; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Anticoagulants; Antiviral Agents; Azithromycin; COVID-19; COVID-19 Drug Treatment; COVID-19 Serotherapy; Disease Progression; Humans; Hydroxychloroquine; Immunization, Passive; Immunoglobulins, Intravenous; Immunomodulation; Interferon-beta; Interleukin 1 Receptor Antagonist Protein; Lopinavir; Nitriles; Protein Kinase Inhibitors; Pyrazoles; Pyrimidines; Ritonavir; SARS-CoV-2 | 2021 |
Insights into antiviral mechanisms of remdesivir, lopinavir/ritonavir and chloroquine/hydroxychloroquine affecting the new SARS-CoV-2.
Topics: Adenosine Monophosphate; Alanine; Animals; Antiviral Agents; Betacoronavirus; Chloroquine; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Drug Combinations; Humans; Hydroxychloroquine; Lopinavir; Pandemics; Pneumonia, Viral; Ritonavir; SARS-CoV-2 | 2020 |
A Review of the Preclinical and Clinical Efficacy of Remdesivir, Hydroxychloroquine, and Lopinavir-Ritonavir Treatments against COVID-19.
Topics: Adenosine Monophosphate; Alanine; Antiviral Agents; Clinical Trials as Topic; COVID-19 Drug Treatment; Drug Therapy, Combination; Humans; Hydroxychloroquine; Lopinavir; Ritonavir; SARS-CoV-2; Treatment Outcome | 2020 |
Evaluation of current medical approaches for COVID-19: a systematic review and meta-analysis.
Topics: Adenosine Monophosphate; Alanine; Antirheumatic Agents; Antiviral Agents; COVID-19; COVID-19 Drug Treatment; COVID-19 Serotherapy; Drug Combinations; Humans; Hydroxychloroquine; Immunization, Passive; Immunoglobulins, Intravenous; Immunologic Factors; Indoles; Lopinavir; Medicine, Chinese Traditional; Ritonavir; SARS-CoV-2; Treatment Outcome | 2021 |
SARS-CoV-2 pharmacologic therapies and their safety/effectiveness according to level of evidence.
Topics: Adenosine Monophosphate; Alanine; Antiviral Agents; Chloroquine; COVID-19; COVID-19 Drug Treatment; Dexamethasone; Drug Combinations; Evidence-Based Medicine; Humans; Hydroxychloroquine; Interferon beta-1b; Lopinavir; Meta-Analysis as Topic; Randomized Controlled Trials as Topic; Ribavirin; Ritonavir; Systematic Reviews as Topic | 2020 |
Repurposing of drugs for COVID-19: a systematic review and meta-analysis.
Topics: COVID-19 Drug Treatment; Drug Repositioning; Humans; Hydroxychloroquine; Lopinavir; Randomized Controlled Trials as Topic; Ritonavir | 2022 |
Randomised controlled trials for COVID-19: evaluation of optimal randomisation methodologies-need for data validation of the completed trials and to improve ongoing and future randomised trial designs.
Topics: COVID-19; COVID-19 Drug Treatment; Critical Illness; Hospitalization; Humans; Hydroxychloroquine; Lopinavir; Mortality; Randomized Controlled Trials as Topic; Ritonavir; Selection Bias | 2021 |
One year update on the COVID-19 pandemic: Where are we now?
Topics: Adenosine Monophosphate; Alanine; Amides; Animals; Antiviral Agents; Chloroquine; Clinical Trials as Topic; Coronavirus; Coronavirus Infections; COVID-19; COVID-19 Vaccines; Drug Combinations; Drug Repositioning; Glucocorticoids; Humans; Hydroxychloroquine; Indoles; Ivermectin; Lopinavir; Mutation; Pandemics; Phytotherapy; Plant Extracts; Pyrazines; Ritonavir; SARS-CoV-2; Spike Glycoprotein, Coronavirus; Tinospora; Viral Zoonoses | 2021 |
Application of machine intelligence technology in the detection of vaccines and medicines for SARS-CoV-2.
Topics: Adenosine Monophosphate; Alanine; Antibodies, Monoclonal, Humanized; Antiviral Agents; Artificial Intelligence; Ascorbic Acid; Chloroquine; COVID-19; COVID-19 Drug Treatment; COVID-19 Vaccines; Deep Learning; Drug Combinations; Drug Development; Drug Repositioning; Humans; Hydroxychloroquine; Immunosuppressive Agents; Lopinavir; Machine Learning; Ribavirin; Ritonavir; Vitamins | 2020 |
Treatment Options for Coronavirus Disease 2019 in Patients With Reduced or Absent Kidney Function.
Topics: Adenosine Monophosphate; Alanine; Amides; Anti-Inflammatory Agents; Antibodies, Monoclonal, Humanized; Antiviral Agents; Chloroquine; COVID-19; COVID-19 Drug Treatment; COVID-19 Serotherapy; COVID-19 Vaccines; Creatinine; Cytidine; Dexamethasone; Drug Combinations; Drug Interactions; Humans; Hydroxychloroquine; Hydroxylamines; Immunization, Passive; Interferons; Janus Kinase Inhibitors; Lopinavir; Pyrazines; Renal Elimination; Renal Insufficiency, Chronic; Renal Replacement Therapy; Ribavirin; Ritonavir; SARS-CoV-2 | 2020 |
Possible treatment and strategies for COVID-19: review and assessment.
Topics: Adenosine Monophosphate; Alanine; Amides; Anti-Bacterial Agents; Anti-Inflammatory Agents; Antibodies, Monoclonal, Humanized; Antibodies, Neutralizing; Antiparasitic Agents; Antiviral Agents; Cannabinoids; Chloroquine; Complement Inactivating Agents; COVID-19; COVID-19 Drug Treatment; COVID-19 Serotherapy; COVID-19 Vaccines; Dexamethasone; Drug Combinations; Enzyme Inhibitors; Humans; Hydroxychloroquine; Immunization, Passive; Indoles; Interferons; Ivermectin; Lopinavir; Nitro Compounds; Pyrazines; Ritonavir; SARS-CoV-2; Teicoplanin; Tetracyclines; Thiazoles | 2020 |
Off-label use of chloroquine, hydroxychloroquine, azithromycin and lopinavir/ritonavir in COVID-19 risks prolonging the QT interval by targeting the hERG channel.
Topics: Azithromycin; Chloroquine; COVID-19; COVID-19 Drug Treatment; Drug Combinations; ERG1 Potassium Channel; Humans; Hydroxychloroquine; Long QT Syndrome; Lopinavir; Off-Label Use; Ritonavir | 2021 |
Antiviral treatment in COVID-19: which is the most promising?-a narrative review.
Topics: Adenosine Monophosphate; Alanine; Amides; Antibodies, Monoclonal, Humanized; Antiviral Agents; Azetidines; Chloroquine; COVID-19; COVID-19 Serotherapy; Drug Combinations; Humans; Hydroxychloroquine; Immunization, Passive; Indoles; Interferons; Ivermectin; Lopinavir; Nitro Compounds; Oseltamivir; Purines; Pyrazines; Pyrazoles; Ribavirin; Ritonavir; Sulfonamides; Thiazoles | 2021 |
A complementary critical appraisal on systematic reviews regarding the most efficient therapeutic strategies for the current COVID-19 (SARS-CoV-2) pandemic.
Topics: Adenosine Monophosphate; Alanine; Amides; Antiviral Agents; Chloroquine; COVID-19; COVID-19 Drug Treatment; Cytokine Release Syndrome; Databases, Factual; Humans; Hydroxychloroquine; Immunoglobulins; Lopinavir; Pandemics; Pyrazines; Respiration, Artificial; Ritonavir; SARS-CoV-2 | 2021 |
COVID-19 and Its Implications for Thrombosis and Anticoagulation.
Topics: Adenosine Monophosphate; Alanine; Ambulatory Care; Antibodies, Antiphospholipid; Antibodies, Monoclonal, Humanized; Anticoagulants; Antirheumatic Agents; Antiviral Agents; COVID-19; COVID-19 Drug Treatment; COVID-19 Serotherapy; Dose-Response Relationship, Drug; Drug Combinations; Duration of Therapy; Glucocorticoids; Hospitalization; Humans; Hydroxychloroquine; Immunization, Passive; Lopinavir; Ritonavir; SARS-CoV-2; Thrombolytic Therapy; Thrombophilia; Thrombosis; Venous Thromboembolism | 2021 |
COVID-19: molecular pathophysiology, genetic evolution and prospective therapeutics-a review.
Topics: Adenosine Monophosphate; Alanine; Amides; Animals; Antiviral Agents; Chloroquine; COVID-19; COVID-19 Serotherapy; Dexamethasone; Drug Repositioning; Evolution, Molecular; Humans; Hydroxychloroquine; Immunization, Passive; Lopinavir; Pandemics; Phylogeny; Prospective Studies; Pyrazines; Ribavirin; Ritonavir; SARS-CoV-2 | 2021 |
[The praise of uncertainty: a systematic living review to evaluate the efficacy and safety of drug treatments for patients with covid-19.]
Topics: Adenosine Monophosphate; Adrenal Cortex Hormones; Alanine; Amides; Antibodies, Monoclonal, Humanized; Antiviral Agents; Combined Modality Therapy; COVID-19; COVID-19 Drug Treatment; COVID-19 Serotherapy; Drug Combinations; Drug Repositioning; Humans; Hydroxychloroquine; Immunization, Passive; Immunoglobulins, Intravenous; Lopinavir; Mesenchymal Stem Cell Transplantation; Pandemics; Pyrazines; Randomized Controlled Trials as Topic; Ritonavir; SARS-CoV-2; Treatment Outcome; Uncertainty | 2021 |
Pharmacological interventions for COVID-19: a systematic review of observational studies and clinical trials.
Topics: Adenosine Monophosphate; Alanine; Amides; Anti-Inflammatory Agents; Antibodies, Monoclonal, Humanized; Antimalarials; Antiviral Agents; Chloroquine; Clinical Trials as Topic; COVID-19; COVID-19 Drug Treatment; COVID-19 Serotherapy; Humans; Hydroxychloroquine; Immunization, Passive; Indoles; Intensive Care Units; Length of Stay; Lopinavir; Methylprednisolone; Observational Studies as Topic; Patient Admission; Pyrazines; Ritonavir; SARS-CoV-2; Survival Rate | 2021 |
QTc prolongation in COVID-19 patients treated with hydroxychloroquine, chloroquine, azithromycin, or lopinavir/ritonavir: A systematic review and meta-analysis.
Topics: Azithromycin; Chloroquine; COVID-19; COVID-19 Drug Treatment; Humans; Hydroxychloroquine; Long QT Syndrome; Lopinavir; Observational Studies as Topic; Ritonavir | 2021 |
Insight in the Current Progress in the Largest Clinical Trials for Covid-19 Drug Management (As of January 2021).
Topics: Adenosine Monophosphate; Alanine; Antibodies, Monoclonal, Humanized; Antiviral Agents; Chloroquine; Clinical Trials as Topic; COVID-19; COVID-19 Drug Treatment; COVID-19 Serotherapy; Dexamethasone; Drug Combinations; Glucocorticoids; Humans; Hydroxychloroquine; Immunization, Passive; Immunologic Factors; Lopinavir; Ritonavir; SARS-CoV-2 | 2021 |
What if COVID-19 affects the child: which weapons and how to use them.
Topics: Adenosine Monophosphate; Adolescent; Age Factors; Alanine; Antibodies, Monoclonal, Humanized; Anticoagulants; Antiviral Agents; Carrier State; Child; Child, Preschool; Chloroquine; Continuous Renal Replacement Therapy; COVID-19; COVID-19 Drug Treatment; COVID-19 Serotherapy; Drug Combinations; Extracorporeal Membrane Oxygenation; Glucocorticoids; Humans; Hydroxychloroquine; Immunization, Passive; Immunoglobulins, Intravenous; Immunologic Factors; Infant; Infant, Newborn; Interferon-alpha; Lopinavir; Oseltamivir; Receptors, Cell Surface; Respiration, Artificial; Ribavirin; Ritonavir; SARS-CoV-2; Severity of Illness Index; Thrombosis | 2021 |
Management of COVID-19 in patients with seizures: Mechanisms of action of potential COVID-19 drug treatments and consideration for potential drug-drug interactions with anti-seizure medications.
Topics: Adenosine Monophosphate; Alanine; Amides; Anti-Inflammatory Agents; Antibodies, Monoclonal, Humanized; Anticonvulsants; Antiviral Agents; Chloroquine; COVID-19; COVID-19 Drug Treatment; Cytochrome P-450 CYP3A Inducers; Dexamethasone; Drug Combinations; Drug Interactions; Enzyme Inhibitors; Epilepsy; Glucocorticoids; Humans; Hydroxychloroquine; Interleukin 1 Receptor Antagonist Protein; Ivermectin; Lopinavir; Pyrazines; Ritonavir; SARS-CoV-2 | 2021 |
Lopinavir/Ritonavir for COVID-19: a Systematic Review and Meta-Analysis.
Topics: COVID-19; COVID-19 Drug Treatment; Drug Therapy, Combination; HIV Protease Inhibitors; Humans; Hydroxychloroquine; Lopinavir; Randomized Controlled Trials as Topic; Retrospective Studies; Ritonavir | 2021 |
How trustworthy guidelines can impact outcomes.
Topics: COVID-19; Humans; Hydroxychloroquine; Lopinavir; Pandemics; SARS-CoV-2 | 2021 |
Umifenovir in hospitalized moderate to severe COVID-19 patients: A randomized clinical trial.
Topics: Adult; Aged; Antiviral Agents; COVID-19 Drug Treatment; Drug Therapy, Combination; Female; Humans; Hydroxychloroquine; Indoles; Interferon beta-1a; Lopinavir; Male; Middle Aged; Ritonavir | 2021 |
COVID-19: potential therapeutics for pediatric patients.
Topics: Adenosine Monophosphate; Alanine; Anti-Inflammatory Agents; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antiviral Agents; Azithromycin; Child; COVID-19 Drug Treatment; Dexamethasone; Humans; Hydroxychloroquine; Ivermectin; Lopinavir; Oseltamivir; SARS-CoV-2; Spike Glycoprotein, Coronavirus | 2021 |
Safety profile of COVID-19 drugs in a real clinical setting.
Topics: Antiviral Agents; Chloroquine; COVID-19 Drug Treatment; Dexamethasone; Drug-Related Side Effects and Adverse Reactions; Humans; Hydroxychloroquine; Ivermectin; Lopinavir; Reproducibility of Results; Ritonavir; SARS-CoV-2 | 2022 |
Adverse effects of remdesivir, hydroxychloroquine and lopinavir/ritonavir when used for COVID-19: systematic review and meta-analysis of randomised trials.
Topics: Adenosine Monophosphate; Alanine; COVID-19 Drug Treatment; Drug Combinations; Humans; Hydroxychloroquine; Lopinavir; Randomized Controlled Trials as Topic; Ritonavir; SARS-CoV-2 | 2022 |
Efficacy of pharmacological interventions in COVID-19: A network meta-analysis.
Topics: Antiviral Agents; COVID-19 Drug Treatment; Dexamethasone; Humans; Hydroxychloroquine; Lopinavir; Network Meta-Analysis; Randomized Controlled Trials as Topic; Treatment Outcome | 2022 |
Remdesivir and three other drugs for hospitalised patients with COVID-19: final results of the WHO Solidarity randomised trial and updated meta-analyses.
Topics: Adenosine Monophosphate; Adult; Alanine; Antiviral Agents; COVID-19 Drug Treatment; Humans; Hydroxychloroquine; Interferon beta-1a; Lopinavir; Oxygen; Randomized Controlled Trials as Topic; Treatment Outcome; World Health Organization | 2022 |
Molnupiravir in COVID-19: A Scoping Review.
Topics: Adrenal Cortex Hormones; Animals; Antiviral Agents; COVID-19 Drug Treatment; Cricetinae; Ferrets; Humans; Hydroxychloroquine; Ivermectin; Lopinavir; Mice; Ritonavir; RNA-Dependent RNA Polymerase; SARS-CoV-2 | 2022 |
Antivirals and the Potential Benefits of Orally Inhaled Drug Administration in COVID-19 Treatment.
Topics: Antiviral Agents; Chloroquine; COVID-19 Drug Treatment; Heparin; Humans; Hydroxychloroquine; Lopinavir; Ritonavir; SARS-CoV-2 | 2022 |
18 trial(s) available for hydroxychloroquine and lopinavir
| Article | Year |
|---|---|
Effectiveness of Interferon Beta 1a, compared to Interferon Beta 1b and the usual therapeutic regimen to treat adults with moderate to severe COVID-19: structured summary of a study protocol for a randomized controlled trial.
Topics: Antiviral Agents; Betacoronavirus; Coronavirus Infections; COVID-19; Drug Combinations; Drug Therapy, Combination; Host-Pathogen Interactions; Humans; Hydroxychloroquine; Interferon beta-1a; Interferon beta-1b; Iran; Lopinavir; Pandemics; Pneumonia, Viral; Randomized Controlled Trials as Topic; Ritonavir; SARS-CoV-2; Severity of Illness Index; Time Factors; Treatment Outcome | 2020 |
Subcutaneous administration of interferon beta-1a for COVID-19: A non-controlled prospective trial.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antiviral Agents; Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Drug Combinations; Drug Therapy, Combination; Female; Humans; Hydroxychloroquine; Injections, Subcutaneous; Interferon beta-1a; Lopinavir; Lung; Male; Middle Aged; Pandemics; Pneumonia, Viral; Prospective Studies; Ritonavir; SARS-CoV-2; Tomography, X-Ray Computed; Treatment Outcome; Young Adult | 2020 |
A Randomized Clinical Trial of the Efficacy and Safety of Interferon β-1a in Treatment of Severe COVID-19.
Topics: Adult; Aged; Antiviral Agents; Atazanavir Sulfate; Betacoronavirus; Cardiovascular Diseases; Comorbidity; Coronavirus Infections; COVID-19; Diabetes Mellitus; Drug Administration Schedule; Drug Combinations; Drug Therapy, Combination; Dyslipidemias; Female; Humans; Hydroxychloroquine; Intensive Care Units; Interferon beta-1a; Length of Stay; Lopinavir; Male; Middle Aged; Neoplasms; Pandemics; Patient Safety; Pneumonia, Viral; Ritonavir; SARS-CoV-2; Survival Analysis; Treatment Outcome | 2020 |
The Australasian COVID-19 Trial (ASCOT) to assess clinical outcomes in hospitalised patients with SARS-CoV-2 infection (COVID-19) treated with lopinavir/ritonavir and/or hydroxychloroquine compared to standard of care: A structured summary of a study prot
Topics: Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Drug Therapy, Combination; Hospitalization; Humans; Hydroxychloroquine; Lopinavir; Pandemics; Pneumonia, Viral; Randomized Controlled Trials as Topic; Ritonavir; SARS-CoV-2; Standard of Care | 2020 |
Safety and effectiveness of azithromycin in patients with COVID-19: An open-label randomised trial.
Topics: Adult; Aged; Anti-Infective Agents; Azithromycin; Betacoronavirus; C-Reactive Protein; Coronavirus Infections; COVID-19; Disease Progression; Drug Combinations; Female; Heart Rate; Humans; Hydroxychloroquine; Intensive Care Units; Lopinavir; Male; Middle Aged; Pandemics; Patient Safety; Pneumonia, Viral; Prognosis; Respiratory Function Tests; Ritonavir; SARS-CoV-2; Survival Analysis; T-Lymphocytes; Tomography, X-Ray Computed; Treatment Outcome | 2020 |
Protocol for the DisCoVeRy trial: multicentre, adaptive, randomised trial of the safety and efficacy of treatments for COVID-19 in hospitalised adults.
Topics: Adenosine Monophosphate; Adult; Alanine; Antiviral Agents; Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Drug Combinations; Drug Therapy, Combination; Early Warning Score; Extracorporeal Membrane Oxygenation; Hospital Mortality; Hospitalization; Humans; Hydroxychloroquine; Interferon beta-1a; Length of Stay; Lopinavir; Oxygen Inhalation Therapy; Pandemics; Pneumonia, Viral; Respiration, Artificial; Ritonavir; SARS-CoV-2; Standard of Care; Treatment Outcome | 2020 |
Safety and efficacy of antiviral combination therapy in symptomatic patients of Covid-19 infection - a randomised controlled trial (SEV-COVID Trial): A structured summary of a study protocol for a randomized controlled trial.
Topics: Administration, Oral; Adult; Antimalarials; Antiviral Agents; Betacoronavirus; Clinical Protocols; Combined Modality Therapy; Coronavirus Infections; COVID-19; Cytochrome P-450 CYP3A Inhibitors; Female; Humans; Hydroxychloroquine; India; Informed Consent; Lopinavir; Male; Pandemics; Pneumonia, Viral; Ribavirin; Ritonavir; Safety; SARS-CoV-2; Time Factors; Treatment Outcome | 2020 |
Evaluating the effects of Intravenous Immunoglobulin (IVIg) on the management of severe COVID-19 cases: A randomized controlled trial.
Topics: Adult; Aged; Antiviral Agents; COVID-19 Drug Treatment; Drug Therapy, Combination; Female; Humans; Hydroxychloroquine; Immunoglobulins, Intravenous; Immunologic Factors; Length of Stay; Lopinavir; Male; Middle Aged; Ritonavir; SARS-CoV-2; Treatment Outcome | 2021 |
Repurposed Antiviral Drugs for Covid-19 - Interim WHO Solidarity Trial Results.
Topics: Adenosine Monophosphate; Aged; Alanine; Antiviral Agents; COVID-19; COVID-19 Drug Treatment; Drug Therapy, Combination; Female; Hospital Mortality; Hospitalization; Humans; Hydroxychloroquine; Intention to Treat Analysis; Interferon beta-1a; Kaplan-Meier Estimate; Length of Stay; Lopinavir; Male; Middle Aged; Respiration, Artificial; Treatment Failure | 2021 |
Effect of Arbidol (Umifenovir) on COVID-19: a randomized controlled trial.
Topics: Adult; Aged; Antiviral Agents; COVID-19 Drug Treatment; Drug Combinations; Female; Humans; Hydroxychloroquine; Indoles; Lopinavir; Male; Middle Aged; Pandemics; Ritonavir; SARS-CoV-2 | 2020 |
The efficacy and safety of Ivermectin in patients with mild and moderate COVID-19: A structured summary of a study protocol for a randomized controlled trial.
Topics: Administration, Oral; Adult; Antiviral Agents; Clinical Trials, Phase III as Topic; COVID-19; COVID-19 Drug Treatment; Drug Therapy, Combination; Female; Humans; Hydroxychloroquine; Intensive Care Units; Interferon beta-1a; Iran; Ivermectin; Length of Stay; Lopinavir; Male; Randomized Controlled Trials as Topic; Ritonavir; SARS-CoV-2; Severity of Illness Index | 2021 |
Safety and effectiveness of high-dose vitamin C in patients with COVID-19: a randomized open-label clinical trial.
Topics: Antiviral Agents; Ascorbic Acid; Body Temperature; COVID-19 Drug Treatment; Female; Humans; Hydroxychloroquine; Intensive Care Units; Length of Stay; Lopinavir; Male; Middle Aged; Oxygen; Respiratory Distress Syndrome; Ritonavir; Treatment Outcome | 2021 |
Effect of Early Treatment With Hydroxychloroquine or Lopinavir and Ritonavir on Risk of Hospitalization Among Patients With COVID-19: The TOGETHER Randomized Clinical Trial.
Topics: Antiviral Agents; Brazil; COVID-19; Drug Monitoring; Drug Therapy, Combination; Early Medical Intervention; Female; Hospitalization; Humans; Hydroxychloroquine; Lopinavir; Male; Medical Futility; Middle Aged; Risk Adjustment; Ritonavir; Symptom Assessment; Treatment Outcome | 2021 |
An open-label randomized controlled trial of the effect of lopinavir/ritonavir, lopinavir/ritonavir plus IFN-β-1a and hydroxychloroquine in hospitalized patients with COVID-19.
Topics: Adult; Antiviral Agents; COVID-19 Drug Treatment; Drug Combinations; Female; Humans; Hydroxychloroquine; Interferon beta-1a; Lopinavir; Male; Middle Aged; Ritonavir; Treatment Outcome | 2021 |
Lopinavir-ritonavir and hydroxychloroquine for critically ill patients with COVID-19: REMAP-CAP randomized controlled trial.
Topics: Adult; Antiviral Agents; Bayes Theorem; COVID-19 Drug Treatment; Critical Illness; Drug Combinations; Humans; Hydroxychloroquine; Lopinavir; Ritonavir; SARS-CoV-2 | 2021 |
Comparing the effectiveness of Atazanavir/Ritonavir/Dolutegravir/Hydroxychloroquine and Lopinavir/Ritonavir/Hydroxychloroquine treatment regimens in COVID-19 patients.
Topics: Antiviral Agents; Atazanavir Sulfate; COVID-19; COVID-19 Drug Treatment; Drug Combinations; Drug Therapy, Combination; Female; Heterocyclic Compounds, 3-Ring; Humans; Hydroxychloroquine; Lopinavir; Male; Middle Aged; Oxazines; Piperazines; Pyridones; Ritonavir; Treatment Outcome | 2021 |
A multi-centre, randomized, double-blind, placebo-controlled clinical trial of the efficacy and safety of chloroquine phosphate, hydroxychloroquine sulphate and lopinavir/ritonavir for the treatment of COVID-19 in Lagos State: study protocol for a randomi
Topics: Chloroquine; COVID-19 Drug Treatment; Humans; Hydroxychloroquine; Lopinavir; Multicenter Studies as Topic; Nigeria; Randomized Controlled Trials as Topic; Ritonavir; SARS-CoV-2 | 2021 |
An open-label randomized, controlled trial of the effect of lopinavir and ritonavir, lopinavir and ritonavir plus interferon-β-1a, and hydroxychloroquine in hospitalized patients with COVID-19: final results.
Topics: Antiviral Agents; COVID-19 Drug Treatment; Drug Combinations; Drug Therapy, Combination; Humans; Hydroxychloroquine; Interferon beta-1a; Lopinavir; Ritonavir | 2022 |
129 other study(ies) available for hydroxychloroquine and lopinavir
| Article | Year |
|---|---|
Perspectives on SARS-CoV-2 Main Protease Inhibitors.
Topics: Antiviral Agents; Coronavirus 3C Proteases; Humans; Protease Inhibitors | 2021 |
Audio Interview: New Research on Possible Treatments for Covid-19.
Topics: Adrenal Cortex Hormones; Anti-Inflammatory Agents, Non-Steroidal; Antiviral Agents; Betacoronavirus; Clinical Trials as Topic; Coronavirus Infections; COVID-19 Drug Treatment; Cross Infection; Diagnosis, Differential; Drug Combinations; Humans; Hydroxychloroquine; Infection Control; Influenza, Human; Lopinavir; Patient Care; Receptors, Virus; Respiration, Artificial; Ritonavir; SARS-CoV-2 | 2020 |
Advance of promising targets and agents against COVID-19 in China.
Topics: Adenine; Adenosine Monophosphate; Alanine; Amides; Antimalarials; Antiviral Agents; Betacoronavirus; China; Chloroquine; Clinical Trials as Topic; Cobicistat; Coronavirus 3C Proteases; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Cysteine Endopeptidases; Dibenzothiepins; Drug Combinations; Drug Discovery; Drug Therapy, Combination; Emtricitabine; Humans; Hydroxychloroquine; Indoles; Lopinavir; Medicine, Chinese Traditional; Morpholines; Oseltamivir; Oxazines; Pandemics; Pneumonia, Viral; Pyrazines; Pyridines; Pyridones; Ritonavir; RNA-Dependent RNA Polymerase; SARS-CoV-2; Spike Glycoprotein, Coronavirus; Tenofovir; Thiepins; Triazines; Viral Nonstructural Proteins | 2020 |
Race to find COVID-19 treatments accelerates.
Topics: Adenosine Monophosphate; Alanine; Antiviral Agents; Betacoronavirus; Biomedical Research; Chloroquine; Clinical Trials as Topic; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Drug Combinations; Humans; Hydroxychloroquine; Lopinavir; Pandemics; Pneumonia, Viral; Ritonavir; SARS-CoV-2; World Health Organization | 2020 |
COVID-19 in kidney transplant recipients.
Topics: Aged; Betacoronavirus; Cobicistat; Colchicine; Coronavirus Infections; COVID-19; Cytokines; Darunavir; Drug Combinations; Female; Humans; Hydroxychloroquine; Immunosuppressive Agents; Kidney Failure, Chronic; Kidney Transplantation; Lopinavir; Male; Middle Aged; Mycophenolic Acid; Pandemics; Pneumonia, Viral; Ritonavir; SARS-CoV-2; Tacrolimus; Transplant Recipients; Treatment Outcome | 2020 |
COVID-19 in the Eastern Mediterranean Region and Saudi Arabia: prevention and therapeutic strategies.
Topics: Antiviral Agents; Betacoronavirus; Communicable Disease Control; Coronavirus Infections; COVID-19; Disease Management; Disease Transmission, Infectious; Humans; Hydroxychloroquine; Lopinavir; Mediterranean Region; Pandemics; Pneumonia, Viral; Ritonavir; SARS-CoV-2; Treatment Outcome | 2020 |
Threatening drug-drug interaction in a kidney transplant patient with coronavirus disease 2019 (COVID-19).
Topics: Adult; Antiviral Agents; Betacoronavirus; C-Reactive Protein; Ciliopathies; Cobicistat; Common Cold; Coronavirus Infections; Cough; COVID-19; COVID-19 Drug Treatment; Cytochrome P-450 CYP3A Inhibitors; Darunavir; Deprescriptions; Drug Combinations; Drug Interactions; Enzyme Inhibitors; Fatigue; Female; Glucocorticoids; Graft Rejection; Humans; Hydroxychloroquine; Immunocompromised Host; Immunosuppressive Agents; Interleukin-10; Interleukin-1beta; Interleukin-6; Interleukin-8; Kidney Diseases, Cystic; Kidney Failure, Chronic; Kidney Transplantation; Leber Congenital Amaurosis; Lopinavir; Methylprednisolone; Optic Atrophies, Hereditary; Pandemics; Pneumonia, Viral; Ritonavir; SARS-CoV-2; Severity of Illness Index; Tacrolimus | 2020 |
SARS-CoV-2: Recent Reports on Antiviral Therapies Based on Lopinavir/Ritonavir, Darunavir/Umifenovir, Hydroxychloroquine, Remdesivir, Favipiravir and other Drugs for the Treatment of the New Coronavirus.
Topics: Adenosine Monophosphate; Alanine; Amides; Antiviral Agents; Betacoronavirus; China; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Darunavir; Drug Combinations; Humans; Hydroxychloroquine; Indoles; Lopinavir; Pandemics; Pneumonia, Viral; Pyrazines; Ritonavir; SARS-CoV-2 | 2020 |
Rigorous Randomized Controlled Trial Implementation in the Era of COVID-19.
Topics: Antiviral Agents; Azithromycin; Betacoronavirus; Clinical Laboratory Techniques; Coronavirus Infections; COVID-19; COVID-19 Testing; Drug Repositioning; Humans; Hydroxychloroquine; Lopinavir; Pandemics; Pneumonia, Viral; Practice Guidelines as Topic; Randomized Controlled Trials as Topic; Ritonavir; Sample Size; SARS-CoV-2; United States | 2020 |
COVID-19 in solid organ transplant recipients: A single-center case series from Spain.
Topics: Aged; Antiviral Agents; Betacoronavirus; Coronavirus Infections; COVID-19; Drug Combinations; Female; Fever; Humans; Hydroxychloroquine; Immunosuppressive Agents; Interferon-beta; Lopinavir; Male; Middle Aged; Organ Transplantation; Pandemics; Pneumonia, Viral; Radiography, Thoracic; Retrospective Studies; Ritonavir; SARS-CoV-2; Spain; Transplant Recipients | 2020 |
Coronavirus Disease 19 (COVID-19) complicated with pneumonia in a patient with rheumatoid arthritis receiving conventional disease-modifying antirheumatic drugs.
Topics: Antirheumatic Agents; Arthritis, Rheumatoid; China; Coronavirus Infections; COVID-19; Drug Combinations; Female; Humans; Hydroxychloroquine; Immunocompromised Host; Lopinavir; Middle Aged; Pandemics; Pneumonia, Viral; Real-Time Polymerase Chain Reaction; Ritonavir; Treatment Outcome | 2020 |
Some drugs for COVID-19.
Topics: Adenosine Monophosphate; Adrenal Cortex Hormones; Alanine; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Anti-Inflammatory Agents, Non-Steroidal; Azithromycin; Betacoronavirus; Chloroquine; Clinical Trials as Topic; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; COVID-19 Serotherapy; Drug Combinations; Drug Repositioning; Humans; Hydroxychloroquine; Immunization, Passive; Lopinavir; Neuraminidase; Pandemics; Pneumonia, Viral; Ritonavir; SARS-CoV-2 | 2020 |
Two distinct cases with COVID-19 in kidney transplant recipients.
Topics: Adult; Antiviral Agents; Azithromycin; Betacoronavirus; Calcineurin Inhibitors; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Drug Combinations; Drug Interactions; Humans; Hydroxychloroquine; Immunosuppressive Agents; Kidney Failure, Chronic; Kidney Transplantation; Lopinavir; Male; Middle Aged; Pandemics; Pneumonia, Viral; Ritonavir; SARS-CoV-2; Tacrolimus; Transplant Recipients | 2020 |
Urgent Guidance for Navigating and Circumventing the QTc-Prolonging and Torsadogenic Potential of Possible Pharmacotherapies for Coronavirus Disease 19 (COVID-19).
Topics: Anti-Infective Agents; Betacoronavirus; Coronavirus Infections; COVID-19; Death, Sudden, Cardiac; Drug Combinations; Drug Monitoring; Drug Repositioning; Electrocardiography; Humans; Hydroxychloroquine; Long QT Syndrome; Lopinavir; Pandemics; Pneumonia, Viral; Risk Adjustment; Ritonavir; SARS-CoV-2; Torsades de Pointes | 2020 |
Favourable outcome of coronavirus disease 2019 in a 1-year-old girl with acute myeloid leukaemia and severe treatment-induced immunosuppression.
Topics: Antineoplastic Agents; Betacoronavirus; Coronavirus Infections; COVID-19; Female; Humans; Hydroxychloroquine; Immune Tolerance; Infant; Leukemia, Myeloid, Acute; Lopinavir; Pandemics; Pneumonia, Viral; Ritonavir; SARS-CoV-2 | 2020 |
Erythema multiforme-like eruption in patients with COVID-19 infection: clinical and histological findings.
Topics: Adrenal Cortex Hormones; Aged; Anti-Bacterial Agents; Antiviral Agents; Azithromycin; C-Reactive Protein; Ceftriaxone; COVID-19; COVID-19 Drug Treatment; Drug Combinations; Erythema Multiforme; Female; Fibrin Fibrinogen Degradation Products; Hospitalization; Humans; Hydroxychloroquine; Lopinavir; Lymphocyte Count; Middle Aged; Ritonavir | 2020 |
Clinical Features and Outcomes of 98 Patients Hospitalized with SARS-CoV-2 Infection in Daegu, South Korea: A Brief Descriptive Study.
Topics: Adult; Aged; Betacoronavirus; Coronavirus Infections; COVID-19; Cytokines; Drug Combinations; Female; Humans; Hydroxychloroquine; Intensive Care Units; Lopinavir; Lymphopenia; Male; Middle Aged; Pandemics; Pneumonia, Viral; Republic of Korea; Retrospective Studies; Ritonavir; SARS-CoV-2 | 2020 |
Biggest COVID-19 trial tests repurposed drugs first.
Topics: Adaptive Clinical Trials as Topic; Azithromycin; Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Dexamethasone; Drug Combinations; Drug Repositioning; Humans; Hydroxychloroquine; Lopinavir; Pandemics; Pneumonia, Viral; Randomized Controlled Trials as Topic; Ritonavir; SARS-CoV-2; Standard of Care; United Kingdom | 2020 |
Abdominal Visceral Infarction in 3 Patients with COVID-19.
Topics: Abdomen; Aged; Anticoagulants; Antiviral Agents; Betacoronavirus; Coronavirus Infections; COVID-19; Drug Combinations; Heparin, Low-Molecular-Weight; Humans; Hydroxychloroquine; Infarction; Italy; Lopinavir; Male; Middle Aged; Pandemics; Pneumonia, Viral; Ritonavir; SARS-CoV-2; Thrombosis; Tomography, X-Ray Computed; Viscera | 2020 |
[The "Historic Study" SOLIDARITY-Research's Answer to the Sars-CoV-2 Pandemic].
Topics: Adenosine Monophosphate; Alanine; Antiviral Agents; Betacoronavirus; Bioethical Issues; Chloroquine; Clinical Trials as Topic; Coronavirus Infections; COVID-19; Drug Combinations; Editorial Policies; Humans; Hydroxychloroquine; International Cooperation; Lopinavir; Pandemics; Pneumonia, Viral; Research Design; Ritonavir; SARS-CoV-2; World Health Organization | 2020 |
In Vitro Data of Current Therapies for SARS-CoV-2.
Topics: Adenosine Monophosphate; Alanine; Betacoronavirus; China; Chloroquine; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Drug Repositioning; Emetine; Homoharringtonine; Humans; Hydroxychloroquine; Ivermectin; Lopinavir; Nitro Compounds; Pandemics; Pneumonia, Viral; SARS-CoV-2; Teicoplanin; Thiazoles | 2020 |
Coronavirus disease 2019 and transplantation: The combination of lopinavir/ritonavir and hydroxychloroquine is responsible for excessive tacrolimus trough level and unfavorable outcome.
Topics: Betacoronavirus; Coronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Humans; Hydroxychloroquine; Lopinavir; Pandemics; Pneumonia, Viral; Ritonavir; SARS-CoV-2; Spain; Tacrolimus; Transplant Recipients | 2020 |
Conduction abnormalities in hydroxychloroquine add on therapy to lopinavir/ritonavir in COVID-19.
Topics: Antiviral Agents; COVID-19; Humans; Hydroxychloroquine; Lopinavir; Ritonavir; SARS-CoV-2 | 2020 |
Coronavirus disease-2019 in cancer patients. A report of the first 25 cancer patients in a western country (Italy).
Topics: Age Factors; Aged; Aged, 80 and over; Antiviral Agents; Azithromycin; Betacoronavirus; Ceftriaxone; Cobicistat; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Darunavir; Drug Therapy, Combination; Female; HIV Protease Inhibitors; Humans; Hydroxychloroquine; Italy; Lopinavir; Male; Methylprednisolone; Middle Aged; Neoplasms; Pandemics; Pneumonia, Viral; Ritonavir; SARS-CoV-2 | 2020 |
Early experience with remdesivir in SARS-CoV-2 pneumonia.
Topics: Adenosine Monophosphate; Alanine; Antiviral Agents; Betacoronavirus; Chemical and Drug Induced Liver Injury; Convalescence; Coronavirus Infections; COVID-19; Critical Illness; Darunavir; Drug Administration Schedule; Drug Combinations; Fatal Outcome; Humans; Hydroxychloroquine; Lopinavir; Multiple Organ Failure; Pandemics; Pneumonia, Viral; Ritonavir; RNA, Viral; SARS-CoV-2; Torsades de Pointes | 2020 |
Steroid-Responsive Encephalitis in Coronavirus Disease 2019.
Topics: Akinetic Mutism; Antiviral Agents; beta 2-Microglobulin; Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Drug Combinations; Electroencephalography; Encephalitis; Glucocorticoids; Humans; Hydroxychloroquine; Interleukin-6; Interleukin-8; Lopinavir; Magnetic Resonance Imaging; Male; Methylprednisolone; Middle Aged; Pandemics; Pneumonia, Viral; Ritonavir; SARS-CoV-2; Treatment Outcome; Tumor Necrosis Factor-alpha | 2020 |
[From empiricism to scientific evidence in antiviral treatment in severe cases of coronavirus infection in times of epidemic].
Topics: Adenosine Monophosphate; Alanine; Antiviral Agents; Betacoronavirus; Chloroquine; Clinical Decision-Making; Clinical Trials as Topic; Coronavirus Infections; Cost-Benefit Analysis; COVID-19; Drug Combinations; Empiricism; Humans; Hydroxychloroquine; Information Dissemination; Lopinavir; Pandemics; Pneumonia, Viral; Reproducibility of Results; Ritonavir; SARS-CoV-2; Viral Load | 2020 |
The liaison between respiratory failure and high blood pressure: evidence from COVID-19 patients.
Topics: Aged; Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Disease Progression; Drug Combinations; Female; Hemodynamics; Humans; Hydroxychloroquine; Hypertension; Italy; Lopinavir; Male; Middle Aged; Oxygen; Pandemics; Pneumonia, Viral; Renin-Angiotensin System; Respiratory Insufficiency; Ritonavir; SARS-CoV-2; Treatment Outcome | 2020 |
Acetic acid disinfection as a potential adjunctive therapy for non-severe COVID-19.
Topics: Acetic Acid; Adult; Aged; Aged, 80 and over; Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Disinfection; Female; Humans; Hydroxychloroquine; Lopinavir; Male; Middle Aged; Pandemics; Pneumonia, Viral; Ritonavir; SARS-CoV-2 | 2020 |
Successful recovery from severe COVID-19 pneumonia after kidney transplantation: The interplay between immunosuppression and novel therapy including tocilizumab.
Topics: Antibodies, Monoclonal, Humanized; Antiviral Agents; COVID-19; Drug Therapy, Combination; Female; Graft Rejection; Heparin, Low-Molecular-Weight; Humans; Hydroxychloroquine; Immunosuppression Therapy; Immunosuppressive Agents; Kidney Transplantation; Lopinavir; Lung; Middle Aged; Prednisolone; Respiration, Artificial; Ritonavir; SARS-CoV-2; Severity of Illness Index; Tomography, X-Ray Computed; Treatment Outcome | 2020 |
Active tuberculosis, sequelae and COVID-19 co-infection: first cohort of 49 cases.
Topics: Adult; Aged; Antitubercular Agents; Antiviral Agents; Azithromycin; Betacoronavirus; Clinical Laboratory Techniques; Cohort Studies; Coinfection; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; COVID-19 Testing; Drug Combinations; Emigrants and Immigrants; Female; Humans; Hydroxychloroquine; Lopinavir; Lung; Male; Middle Aged; Mortality; Pandemics; Pneumonia, Viral; Ritonavir; SARS-CoV-2; Tomography, X-Ray Computed; Tuberculosis; Tuberculosis, Pulmonary | 2020 |
The effect of potential therapeutic agents on QT interval in patients with COVID-19 Infection: The importance of close monitoring and correction of electrolytes.
Topics: Antiviral Agents; Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Drug Combinations; Drug Monitoring; Heart Conduction System; Humans; Hydroxychloroquine; Hypokalemia; Long QT Syndrome; Lopinavir; Magnesium; Pandemics; Pneumonia, Viral; Potassium; Retrospective Studies; Ritonavir; SARS-CoV-2 | 2020 |
In vitro activity of lopinavir/ritonavir and hydroxychloroquine against severe acute respiratory syndrome coronavirus 2 at concentrations achievable by usual doses.
Topics: Animals; Anti-Infective Agents; Betacoronavirus; Chlorocebus aethiops; Drug Combinations; Hydroxychloroquine; Lopinavir; Microbial Sensitivity Tests; Ritonavir; SARS-CoV-2; Vero Cells | 2020 |
The Good, the Bad, and the Hoax: When Publication Instantaneously Impacts Treatment Strategies for COVID-19.
Topics: Antiviral Agents; Azithromycin; Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Deception; Drug Combinations; France; Humans; Hydroxychloroquine; Lopinavir; Pandemics; Pneumonia, Viral; Ritonavir; SARS-CoV-2; Scholarly Communication | 2020 |
The rationale for Low-Molecular Weight Heparin (LMWH) use in SARS-CoV-2 infection
Topics: Adenosine Monophosphate; Alanine; Anticoagulants; Antiviral Agents; Biomarkers; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Critical Care; Disease Management; Double-Blind Method; Drug Combinations; Drug Therapy, Combination; Embolism; Endothelium, Vascular; Heparin, Low-Molecular-Weight; Humans; Hydroxychloroquine; Interferon beta-1b; Lopinavir; Macrophage Activation; Pandemics; Pneumonia, Viral; Pulmonary Fibrosis; Randomized Controlled Trials as Topic; Ritonavir; Thromboembolism; Thrombophilia; Thrombosis | 2020 |
Hospital Pharmacy Compounding against COVID-19 pandemic.
Topics: Administration, Oral; Antiviral Agents; Betacoronavirus; Blood Component Transfusion; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Disinfection; Drug Administration Routes; Drug Compounding; Drug Interactions; Drug Stability; Equipment Contamination; Excipients; Forecasting; Home Care Services; Humans; Hydroxychloroquine; Infusions, Intravenous; Lopinavir; Pandemics; Personal Protective Equipment; Pharmacy Service, Hospital; Platelet-Rich Plasma; Pneumonia, Viral; Ritonavir; SARS-CoV-2; Solutions | 2020 |
Lopinavir-ritonavir versus hydroxychloroquine for viral clearance and clinical improvement in patients with mild to moderate coronavirus disease 2019.
Topics: Aged; Aged, 80 and over; Antiviral Agents; COVID-19; COVID-19 Drug Treatment; Drug Combinations; Female; Humans; Hydroxychloroquine; Lopinavir; Male; Middle Aged; Retrospective Studies; Ritonavir; SARS-CoV-2; Time Factors; Treatment Outcome; Viral Load | 2021 |
COVID-19 research: an opinion piece.
Topics: Anti-Retroviral Agents; Betacoronavirus; Coronavirus Infections; COVID-19; Drug Combinations; Drug Repositioning; Humans; Hydroxychloroquine; Lopinavir; Pandemics; Pneumonia, Viral; Research; Ritonavir; SARS-CoV-2; Tenofovir; Time Factors | 2020 |
Five severe COVID-19 pneumonia patients treated with triple combination therapy with lopinavir/ritonavir, hydroxychloroquine, and interferon β-1b.
Topics: Adjuvants, Immunologic; Adult; Aged; Antimalarials; Antiviral Agents; Betacoronavirus; Coronavirus Infections; COVID-19; Drug Therapy, Combination; Female; Humans; Hydroxychloroquine; Interferon beta-1b; Lopinavir; Male; Middle Aged; Pandemics; Pneumonia; Pneumonia, Viral; Ritonavir; SARS-CoV-2; Treatment Outcome | 2020 |
The clinical value of two combination regimens in the Management of Patients Suffering from Covid-19 pneumonia: a single centered, retrospective, observational study.
Topics: Adult; Aged; Azithromycin; COVID-19; COVID-19 Drug Treatment; Drug Combinations; Drug Therapy, Combination; Female; Hospitalization; Humans; Hydroxychloroquine; Iran; Length of Stay; Levofloxacin; Lopinavir; Male; Meropenem; Middle Aged; Naproxen; Oseltamivir; Pneumonia, Viral; Prednisolone; Retrospective Studies; Ritonavir; Treatment Outcome; Vancomycin | 2020 |
Clinical characteristics and management of a liver transplanted patient admitted with SARS-CoV-2 infection.
Topics: Antiviral Agents; Comorbidity; COVID-19; COVID-19 Drug Treatment; Humans; Hydroxychloroquine; Immunosuppression Therapy; Liver Diseases; Liver Transplantation; Lopinavir; Lung; Male; Meropenem; Middle Aged; Ritonavir; SARS-CoV-2 | 2020 |
Verapamil as treatment for refractory status epilepticus secondary to PRES syndrome on a SARS-Cov-2 infected patient.
Topics: Aged; Anemia; Anticoagulants; Anticonvulsants; Antiviral Agents; Betacoronavirus; Calcium Channel Blockers; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Drug Combinations; Enzyme Inhibitors; Humans; Hydroxychloroquine; Lopinavir; Lymphopenia; Male; Pandemics; Pneumonia, Viral; Posterior Leukoencephalopathy Syndrome; Ritonavir; SARS-CoV-2; Status Epilepticus; Verapamil | 2020 |
Rhabdomyolysis as an initial presentation in a patient diagnosed with COVID-19.
Topics: Aged; Anti-Bacterial Agents; Antibodies, Monoclonal, Humanized; Anticoagulants; Azithromycin; Betacoronavirus; Bicarbonates; Ceftriaxone; Coronavirus Infections; COVID-19; Cytochrome P-450 CYP3A Inhibitors; Enoxaparin; Enzyme Inhibitors; Fluid Therapy; Humans; Hydroxychloroquine; Lopinavir; Lung; Male; Pandemics; Pneumonia, Viral; Respiration, Artificial; Rhabdomyolysis; Ritonavir; SARS-CoV-2; Tomography, X-Ray Computed; Treatment Outcome | 2020 |
Imatinib for COVID-19: A case report.
Topics: Adult; Betacoronavirus; Biomarkers; C-Reactive Protein; Coronavirus Infections; COVID-19; Drug Combinations; Female; Humans; Hydroxychloroquine; Imatinib Mesylate; Lopinavir; Lung; Pandemics; Pneumonia, Viral; Protein Kinase Inhibitors; Ritonavir; SARS-CoV-2; Tomography, X-Ray Computed; Treatment Outcome | 2020 |
Clinical course, severity and mortality in a cohort of patients with COVID-19 with rheumatic diseases.
Topics: Adult; Aged; Antirheumatic Agents; Antiviral Agents; Arthritis, Psoriatic; Arthritis, Rheumatoid; Azithromycin; Betacoronavirus; Cohort Studies; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Drug Combinations; Female; Glucocorticoids; Humans; Hydroxychloroquine; Immunoglobulins, Intravenous; Immunologic Factors; Lopinavir; Lupus Erythematosus, Systemic; Male; Middle Aged; Pandemics; Pneumonia, Viral; Retrospective Studies; Rheumatic Diseases; Ritonavir; SARS-CoV-2; Severity of Illness Index; Spondylarthropathies | 2020 |
Anticancer drugs and COVID-19 antiviral treatments in patients with cancer: What can we safely use?
Topics: Amides; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Antineoplastic Agents, Immunological; Antiviral Agents; Betacoronavirus; Chemical and Drug Induced Liver Injury; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Cytochrome P-450 Enzyme System; Drug Combinations; Drug Interactions; Histone Deacetylase Inhibitors; Humans; Hydroxychloroquine; Immunosuppression Therapy; Kidney Diseases; Long QT Syndrome; Lopinavir; Neoplasms; Pandemics; Pneumonia, Viral; Poly(ADP-ribose) Polymerase Inhibitors; Proteasome Inhibitors; Protein Kinase Inhibitors; Pyrazines; Ritonavir; SARS-CoV-2 | 2020 |
Convalescent Plasma Therapy in Coronavirus Disease 2019: a Case Report and Suggestions to Overcome Obstacles.
Topics: Aged; Antibodies, Neutralizing; Antiviral Agents; Betacoronavirus; Blood Grouping and Crossmatching; Coronavirus Infections; COVID-19; COVID-19 Serotherapy; Drug Combinations; Humans; Hydroxychloroquine; Immunization, Passive; Lopinavir; Male; Pandemics; Pneumonia, Viral; Republic of Korea; Ritonavir; SARS-CoV-2; Transfusion-Related Acute Lung Injury | 2020 |
Effect of Systemic Inflammatory Response to SARS-CoV-2 on Lopinavir and Hydroxychloroquine Plasma Concentrations.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antiviral Agents; Betacoronavirus; Biomarkers; C-Reactive Protein; Coronavirus Infections; COVID-19; Cytokine Release Syndrome; Drug Administration Schedule; Drug Combinations; Female; Hospitals, University; Humans; Hydroxychloroquine; Length of Stay; Lopinavir; Male; Middle Aged; Pandemics; Pneumonia, Viral; Retrospective Studies; Ritonavir; SARS-CoV-2; Severity of Illness Index; Survival Analysis | 2020 |
Baricitinib as rescue therapy in a patient with COVID-19 with no complete response to sarilumab.
Topics: Acute Disease; Aged; Antibodies, Monoclonal, Humanized; Antiviral Agents; Azetidines; Azithromycin; Betacoronavirus; Coronavirus Infections; COVID-19; Drug Combinations; Drug Repositioning; Humans; Hydroxychloroquine; Lopinavir; Male; Pandemics; Pneumonia, Viral; Purines; Pyrazoles; Respiratory Insufficiency; Ritonavir; SARS-CoV-2; Sulfonamides; Treatment Outcome | 2020 |
Comparison of hydroxychloroquine, lopinavir/ritonavir, and standard of care in critically ill patients with SARS-CoV-2 pneumonia: an opportunistic retrospective analysis.
Topics: Aged; Coronavirus Infections; COVID-19; Critical Illness; Drug Combinations; Female; Humans; Hydroxychloroquine; Lopinavir; Male; Middle Aged; Pandemics; Pneumonia, Viral; Retrospective Studies; Ritonavir; Standard of Care; Treatment Outcome | 2020 |
Determinants of COVID-19 disease severity in patients with underlying rheumatic disease.
Topics: Age Factors; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antirheumatic Agents; Antiviral Agents; Betacoronavirus; C-Reactive Protein; Cardiovascular Diseases; Comorbidity; Coronavirus Infections; COVID-19; Diabetes Mellitus; Drug Combinations; Dyslipidemias; Female; Ferritins; Fibrin Fibrinogen Degradation Products; Hospitalization; Humans; Hydroxychloroquine; Hypertension; Interleukin 1 Receptor Antagonist Protein; L-Lactate Dehydrogenase; Length of Stay; Lopinavir; Lung Diseases, Interstitial; Male; Mortality; Odds Ratio; Pandemics; Pneumonia, Viral; Prospective Studies; Rheumatic Diseases; Risk Factors; Ritonavir; SARS-CoV-2; Severity of Illness Index; Spain | 2020 |
Description of 3 patients with myasthenia gravis and COVID-19.
Topics: Adult; Aged; Azithromycin; Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Diabetes Mellitus, Type 2; Female; Humans; Hydroxychloroquine; Hypertension; Hypothyroidism; Immunocompromised Host; Immunoglobulins, Intravenous; Immunosuppressive Agents; Lopinavir; Male; Myasthenia Gravis; Pandemics; Plasmapheresis; Pneumonia, Viral; Ritonavir; SARS-CoV-2; Treatment Outcome | 2020 |
Association between treatment with colchicine and improved survival in a single-centre cohort of adult hospitalised patients with COVID-19 pneumonia and acute respiratory distress syndrome.
Topics: Aged; Aged, 80 and over; Anti-Inflammatory Agents; Antiviral Agents; Betacoronavirus; Case-Control Studies; Cohort Studies; Colchicine; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Dexamethasone; Drug Combinations; Enzyme Inhibitors; Female; Hospitalization; Humans; Hydroxychloroquine; Italy; Lopinavir; Male; Middle Aged; Pandemics; Pneumonia, Viral; Proof of Concept Study; Proportional Hazards Models; Respiratory Distress Syndrome; Ritonavir; SARS-CoV-2; Survival Rate | 2020 |
Clinical features and prognosis of COVID-19 in people with spinal cord injury: a case-control study.
Topics: Adult; Aged; Anti-Bacterial Agents; Antibodies, Monoclonal, Humanized; Anticoagulants; Antiviral Agents; Azithromycin; Betacoronavirus; Case-Control Studies; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Drug Combinations; Enzyme Inhibitors; Female; Heparin, Low-Molecular-Weight; Humans; Hydroxychloroquine; Italy; Lopinavir; Male; Middle Aged; Oxygen Inhalation Therapy; Pandemics; Pneumonia, Viral; Prognosis; Rehabilitation Centers; Ritonavir; SARS-CoV-2; Spinal Cord Injuries | 2020 |
Coronavirus disease 2019 in patients with HIV in the province of Araba, Basque Country, Spain.
Topics: Adult; Aged; Anti-Retroviral Agents; Antiviral Agents; Betacoronavirus; CD4 Lymphocyte Count; Coinfection; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Female; Hepatitis C, Chronic; HIV Infections; Humans; Hydroxychloroquine; Interferon beta-1b; Lopinavir; Male; Middle Aged; Pandemics; Pneumonia, Viral; Protective Factors; Retrospective Studies; Risk Factors; SARS-CoV-2; Severity of Illness Index; Spain; Sustained Virologic Response; Viral Load | 2020 |
[Therapeutic agents tested in 238 COVID-19 hospitalized patients and their relationship with mortality].
Topics: Adrenal Cortex Hormones; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Antibodies, Monoclonal, Humanized; Antiviral Agents; Azithromycin; Betacoronavirus; Comorbidity; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Drug Therapy, Combination; Female; Humans; Hydroxychloroquine; Inpatients; Lopinavir; Male; Pandemics; Pneumonia, Viral; Proportional Hazards Models; Retrospective Studies; Ritonavir; SARS-CoV-2; Spain; Treatment Outcome | 2020 |
Hydroxychloroquine versus lopinavir/ritonavir in severe COVID-19 patients : Results from a real-life patient cohort.
Topics: Adolescent; Aged; Aged, 80 and over; COVID-19 Drug Treatment; Female; Humans; Hydroxychloroquine; Lopinavir; Male; Middle Aged; Ritonavir; SARS-CoV-2 | 2021 |
Early administration of lopinavir/ritonavir plus hydroxychloroquine does not alter the clinical course of SARS-CoV-2 infection: A retrospective cohort study.
Topics: Aged; Antiviral Agents; COVID-19 Drug Treatment; Drug Combinations; Female; Humans; Hydroxychloroquine; Italy; Lopinavir; Male; Middle Aged; Retrospective Studies; Ritonavir; SARS-CoV-2 | 2021 |
Evaluation of retinotoxicity of COVID-19 treatment: Hydroxychloroquine and lopinavir/ritonavir.
Topics: Antimalarials; Antiviral Agents; COVID-19; COVID-19 Drug Treatment; Cross-Sectional Studies; Drug Combinations; Female; Humans; Hydroxychloroquine; Lopinavir; Male; Middle Aged; Optical Imaging; Retina; Ritonavir; Tomography, Optical Coherence | 2021 |
Coronavirus disease 2019 (COVID-19) in autoimmune and inflammatory conditions: clinical characteristics of poor outcomes.
Topics: Aged; Anti-Bacterial Agents; Antibodies, Monoclonal, Humanized; Antirheumatic Agents; Antiviral Agents; Arthritis, Psoriatic; Arthritis, Rheumatoid; Autoimmune Diseases; Azithromycin; Betacoronavirus; Comorbidity; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Drug Combinations; Female; Glucocorticoids; Hospitalization; Humans; Hydroxychloroquine; Immunosuppressive Agents; Logistic Models; Lopinavir; Lung Diseases; Lupus Erythematosus, Systemic; Male; Middle Aged; Multivariate Analysis; Pandemics; Pneumonia, Viral; Retrospective Studies; Ritonavir; SARS-CoV-2; Severity of Illness Index; Sex Factors; Spain | 2020 |
Clinical outcomes of hospitalised patients with COVID-19 and chronic inflammatory and autoimmune rheumatic diseases: a multicentric matched cohort study.
Topics: Adenosine Monophosphate; Age Factors; Aged; Alanine; Antiviral Agents; Arthritis, Psoriatic; Arthritis, Rheumatoid; Betacoronavirus; Cardiovascular Diseases; Case-Control Studies; Cohort Studies; Comorbidity; Connective Tissue Diseases; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Drug Combinations; Female; Glucocorticoids; Hospitalization; Humans; Hydroxychloroquine; Immunosuppressive Agents; Logistic Models; Lopinavir; Lupus Erythematosus, Systemic; Male; Middle Aged; Obesity; Pandemics; Pneumonia, Viral; Polymyalgia Rheumatica; Prognosis; Rheumatic Diseases; Risk Factors; Ritonavir; SARS-CoV-2; Severity of Illness Index; Sex Factors; Sjogren's Syndrome; Spondylarthropathies | 2020 |
First report on clinical and radiological features of COVID-19 pneumonitis in a Caucasian population: Factors predicting fibrotic evolution.
Topics: Aged; Aged, 80 and over; Antiviral Agents; Betacoronavirus; Coronavirus Infections; COVID-19; Drug Combinations; Female; Humans; Hydroxychloroquine; Lopinavir; Male; Middle Aged; Pandemics; Pneumonia, Viral; Pulmonary Fibrosis; Radiography; Retrospective Studies; Ritonavir; SARS-CoV-2; Tomography, X-Ray Computed | 2020 |
Predictive factors for cardiac conduction abnormalities with hydroxychloroquine-containing combinations for COVID-19.
Topics: Aged; Anti-Infective Agents; Azithromycin; Betacoronavirus; Biomarkers; Coronavirus Infections; COVID-19; Disease Progression; Drug Combinations; Female; Humans; Hydroxychloroquine; Intensive Care Units; Long QT Syndrome; Lopinavir; Lymphocytes; Male; Middle Aged; Neutrophils; Pandemics; Pneumonia, Viral; Prognosis; Proportional Hazards Models; Retrospective Studies; Ritonavir; SARS-CoV-2; Treatment Outcome; Troponin I | 2020 |
A novel approach to managing COVID-19 patients; results of lopinavir plus doxycycline cohort.
Topics: Aged; Aged, 80 and over; Cohort Studies; COVID-19 Drug Treatment; Doxycycline; Drug Therapy, Combination; Female; Humans; Hydroxychloroquine; Lopinavir; Male; Middle Aged; SARS-CoV-2 | 2021 |
Favourable outcome of coronavirus disease 2019 in a patient with anaplastic lymphoma kinase-positive non-small-cell lung cancer receiving alectinib.
Topics: Aged; Anaplastic Lymphoma Kinase; Anti-HIV Agents; Betacoronavirus; Carbazoles; Carcinoma, Non-Small-Cell Lung; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Drug Combinations; Humans; Hydroxychloroquine; Lopinavir; Lung; Lung Neoplasms; Male; Masks; Noninvasive Ventilation; Pandemics; Piperidines; Pneumonia, Viral; Ritonavir; SARS-CoV-2; Tomography, X-Ray Computed; Treatment Outcome | 2020 |
Viral exanthema as manifestation of SARS-CoV-2 infection: A case report.
Topics: Administration, Topical; Adult; Antiviral Agents; Azithromycin; Betacoronavirus; Clinical Laboratory Techniques; Coronavirus Infections; COVID-19; COVID-19 Testing; Drug Combinations; Exanthema; Female; Glucocorticoids; Humans; Hydroxychloroquine; Lopinavir; Pandemics; Pneumonia, Viral; Ritonavir; SARS-CoV-2; Symptom Assessment; Treatment Outcome | 2020 |
[Skin manifestations associated with the new coronavirus SARS-CoV-2 disease].
Topics: Anti-Inflammatory Agents; Antiviral Agents; Benzimidazoles; Betacoronavirus; Betamethasone; Causality; Coronavirus Infections; COVID-19; Drug Eruptions; Drug Therapy, Combination; Humans; Hydroxychloroquine; Lopinavir; Male; Middle Aged; Pandemics; Piperidines; Pneumonia, Viral; Prednisone; Ritonavir; SARS-CoV-2; Skin Diseases, Viral | 2020 |
Clinical improvement in a patient with severe coronavirus disease 2019 after administration of hydroxychloroquine and continuous hemodiafiltlation with nafamostat mesylate.
Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Antiviral Agents; Benzamidines; Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Drug Combinations; Guanidines; Hemodiafiltration; Humans; Hydroxychloroquine; Japan; Lopinavir; Male; Pandemics; Pneumonia, Viral; Respiratory Insufficiency; Ritonavir; SARS-CoV-2; Treatment Outcome | 2020 |
Chest Computed Tomography Findings in Asymptomatic Patients with COVID-19.
Topics: Aged; Aged, 80 and over; Antiviral Agents; Asymptomatic Infections; Bronchiectasis; Bronchioles; Bronchography; COVID-19; COVID-19 Drug Treatment; Drug Combinations; Enzyme Inhibitors; Female; Humans; Hydroxychloroquine; Lopinavir; Lung; Male; Middle Aged; Radiography, Thoracic; Republic of Korea; Retrospective Studies; Ritonavir; SARS-CoV-2; Tomography, X-Ray Computed | 2020 |
Safety assessment of drug combinations used in COVID-19 treatment: in silico toxicogenomic data-mining approach.
Topics: Antiviral Agents; Azithromycin; Betacoronavirus; Chloroquine; Computer Simulation; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Data Mining; Databases, Genetic; Drug Therapy, Combination; Gene Regulatory Networks; Humans; Hydroxychloroquine; Lopinavir; Pandemics; Pneumonia, Viral; Ritonavir; SARS-CoV-2; Toxicogenetics | 2020 |
Characteristics of COVID-19 clinical trials registered with ClinicalTrials.gov: cross-sectional analysis.
Topics: Antibodies, Monoclonal, Humanized; Antiviral Agents; Azithromycin; Betacoronavirus; Chloroquine; Clinical Trials as Topic; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; COVID-19 Serotherapy; Double-Blind Method; Drug Combinations; Humans; Hydroxychloroquine; Immunization, Passive; Lopinavir; Pandemics; Pneumonia, Viral; Registries; Ritonavir; SARS-CoV-2; Single-Blind Method; Stem Cell Transplantation | 2020 |
Sex Differences in Reported Adverse Drug Reactions to COVID-19 Drugs in a Global Database of Individual Case Safety Reports.
Topics: Abdominal Pain; Adenosine Monophosphate; Alanine; Antibodies, Monoclonal, Humanized; Antiviral Agents; Azithromycin; Chemical and Drug Induced Liver Injury; Chloroquine; COVID-19 Drug Treatment; Databases, Pharmaceutical; Diarrhea; Drug Combinations; Drug Eruptions; Drug Repositioning; Drug-Related Side Effects and Adverse Reactions; Female; Humans; Hydroxychloroquine; Long QT Syndrome; Lopinavir; Male; Nausea; Oseltamivir; Ritonavir; Sex Distribution; Sex Factors; Vomiting | 2020 |
Baricitinib improves respiratory function in patients treated with corticosteroids for SARS-CoV-2 pneumonia: an observational cohort study.
Topics: Aged; Antiviral Agents; Azetidines; Cohort Studies; COVID-19; COVID-19 Drug Treatment; Drug Combinations; Drug Therapy, Combination; Endothelium, Vascular; Enzyme Inhibitors; Female; Fibrin Fibrinogen Degradation Products; Glucocorticoids; Humans; Hydroxychloroquine; Hypoxia; Immunoglobulins, Intravenous; Immunologic Factors; Interferon beta-1b; Janus Kinase Inhibitors; Lopinavir; Lung; Male; Methylprednisolone; Middle Aged; Oximetry; Oxygen Inhalation Therapy; Prospective Studies; Purines; Pyrazoles; Ritonavir; SARS-CoV-2; Severity of Illness Index; Sulfonamides | 2021 |
COVID-19 outbreak in Italy: Clinical-radiological presentation and outcome in three oncologic patients.
Topics: Aged; Anti-Bacterial Agents; Antiviral Agents; Betacoronavirus; Carcinoma, Squamous Cell; Coronavirus Infections; COVID-19; Disease Outbreaks; Drug Therapy, Combination; Esophageal Neoplasms; Fatal Outcome; Humans; Hydroxychloroquine; Italy; Lopinavir; Lung Neoplasms; Lymphoma, Non-Hodgkin; Male; Middle Aged; Neoplasms; Pandemics; Pneumonia, Viral; Ritonavir; SARS-CoV-2; Tomography, X-Ray Computed; Treatment Outcome | 2021 |
Acute aortic dissection in a patient with Williams syndrome infected by COVID-19.
Topics: Adolescent; Anti-Bacterial Agents; Antiviral Agents; Aortic Aneurysm; Aortic Dissection; Aortic Stenosis, Supravalvular; Aortitis; Azithromycin; COVID-19; COVID-19 Drug Treatment; Drug Combinations; Enzyme Inhibitors; Fatal Outcome; Glucocorticoids; Humans; Hydroxychloroquine; Immunoglobulins, Intravenous; Immunologic Factors; Lopinavir; Male; Methylprednisolone; Oseltamivir; Recurrence; Ritonavir; SARS-CoV-2; Systemic Inflammatory Response Syndrome; Williams Syndrome | 2021 |
Proinflammatory cytokines are associated with prolonged viral RNA shedding in COVID-19 patients.
Topics: Adrenal Cortex Hormones; Adult; Aged; Aged, 80 and over; China; Comorbidity; COVID-19; COVID-19 Drug Treatment; Cytokine Release Syndrome; Diabetes Mellitus; Drug Combinations; Female; Hospitalization; Humans; Hydroxychloroquine; Hypertension; Interferons; Lopinavir; Lymphopenia; Male; Middle Aged; Receptors, Interleukin-2; Retrospective Studies; Risk Factors; Ritonavir; RNA, Viral; SARS-CoV-2; Severity of Illness Index; Tumor Necrosis Factor-alpha; Virus Shedding | 2020 |
A case of COVID-19 Convalescent Plasma Donation in Greece: Directed donation for compassionate use in the donor's critically ill father.
Topics: Adrenal Cortex Hormones; Aged; Anti-Bacterial Agents; Antifungal Agents; Antiviral Agents; Cardiotonic Agents; Combined Modality Therapy; Compassionate Use Trials; COVID-19; COVID-19 Drug Treatment; COVID-19 Serotherapy; Directed Tissue Donation; Drug Resistance, Multiple; Drug Substitution; Drug Therapy, Combination; Fatal Outcome; Greece; Humans; Hydroxychloroquine; Immunization, Passive; Lopinavir; Male; Respiration, Artificial; Ritonavir; Shock, Septic; Superinfection; Time-to-Treatment | 2020 |
Psychiatric Disorders and Hydroxychloroquine for Coronavirus Disease 2019 (COVID-19): A VigiBase Study.
Topics: Adenosine Monophosphate; Adult; Aged; Aged, 80 and over; Alanine; Antibodies, Monoclonal, Humanized; Antiviral Agents; COVID-19 Drug Treatment; Databases, Pharmaceutical; Drug Combinations; Female; Hallucinations; Humans; Hydroxychloroquine; Lopinavir; Male; Mental Disorders; Middle Aged; Psychoses, Substance-Induced; Ritonavir; Self-Injurious Behavior; Suicide; Suicide, Attempted; Young Adult | 2020 |
Comparison of antiviral effect for mild-to-moderate COVID-19 cases between lopinavir/ritonavir versus hydroxychloroquine: A nationwide propensity score-matched cohort study.
Topics: Adult; Antiviral Agents; COVID-19; COVID-19 Drug Treatment; Drug Therapy, Combination; Female; Humans; Hydroxychloroquine; Lopinavir; Male; Middle Aged; Propensity Score; Retrospective Studies; Ritonavir; SARS-CoV-2; Virus Shedding; Young Adult | 2021 |
Drug-Drug Interactions and Prescription Appropriateness in Patients with COVID-19: A Retrospective Analysis from a Reference Hospital in Northern Italy.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; COVID-19; COVID-19 Drug Treatment; Drug Interactions; Drug Prescriptions; Female; Hospitals; Humans; Hydroxychloroquine; Italy; Lopinavir; Male; Middle Aged; Pandemics; Polypharmacy; Referral and Consultation; Retrospective Studies; Risk Factors; Ritonavir; Young Adult | 2020 |
Effectiveness of lopinavir/ritonavir on COVID-19-related pneumonia in a child with COVID-19-associated Kawasaki disease.
Topics: Ampicillin; Anti-Bacterial Agents; Anticoagulants; Antiviral Agents; Azithromycin; Child; COVID-19; COVID-19 Drug Treatment; COVID-19 Nucleic Acid Testing; COVID-19 Serological Testing; Drug Combinations; Enoxaparin; Humans; Hydroxychloroquine; Hypoxia; Immunoglobulins, Intravenous; Immunologic Factors; Lopinavir; Lung; Male; Mucocutaneous Lymph Node Syndrome; Oseltamivir; Oxygen Inhalation Therapy; Ritonavir; Sulbactam; Tomography, X-Ray Computed | 2021 |
Broncho-alveolar inflammation in COVID-19 patients: a correlation with clinical outcome.
Topics: Adenosine Monophosphate; Adrenal Cortex Hormones; Aged; Alanine; Antibodies, Monoclonal, Humanized; Antiviral Agents; Betacoronavirus; Bronchoalveolar Lavage; Bronchoalveolar Lavage Fluid; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Drug Combinations; Female; Humans; Hydroxychloroquine; Inflammation; Intensive Care Units; Interleukin-10; Interleukin-6; Interleukin-8; Italy; Leukocytes; Leukocytes, Mononuclear; Lopinavir; Lung; Lymphocytes; Macrophages, Alveolar; Male; Microscopy, Electron, Transmission; Middle Aged; Neutrophils; Pandemics; Pneumonia, Viral; Prognosis; Prospective Studies; Respiration, Artificial; Ritonavir; SARS-CoV-2; Spike Glycoprotein, Coronavirus; Survival Rate; Virion | 2020 |
Prognostic factors and predictors of outcome in patients with COVID-19 and related pneumonia: a retrospective cohort study.
Topics: Aged; Aged, 80 and over; Anticoagulants; Antiviral Agents; Cardiovascular Diseases; Comorbidity; COVID-19; COVID-19 Drug Treatment; Enoxaparin; Female; Humans; Hydroxychloroquine; Italy; Lopinavir; Male; Prognosis; Retrospective Studies; Risk Factors; Ritonavir; Treatment Outcome | 2020 |
Safety of hydroxychloroquine and darunavir or lopinavir in COVID-19 infection.
Topics: Antiviral Agents; Cohort Studies; COVID-19; COVID-19 Drug Treatment; Darunavir; Drug Therapy, Combination; Electrocardiography; France; Humans; Hydroxychloroquine; Long QT Syndrome; Lopinavir; SARS-CoV-2; Severity of Illness Index; Treatment Outcome | 2021 |
Prescribing practices of lopinavir/ritonavir, hydroxychloroquine and azithromycin during the COVID-19 epidemic crisis and pharmaceutical interventions in a French teaching hospital.
Topics: Adult; Aged; Antiviral Agents; Azithromycin; COVID-19 Drug Treatment; Drug Combinations; Drug Prescriptions; Female; France; Hospitals, Teaching; Humans; Hydroxychloroquine; Lopinavir; Male; Middle Aged; Pandemics; Patient Safety; Pharmacists; Physicians; Retrospective Studies; Ritonavir | 2021 |
COVID-19 in hospitalised patients in Spain: a cohort study in Madrid.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antiviral Agents; Comorbidity; COVID-19; COVID-19 Drug Treatment; Female; Hospital Mortality; Hospitalization; Humans; Hydroxychloroquine; Immunosuppressive Agents; Intensive Care Units; Lopinavir; Male; Middle Aged; Respiratory Distress Syndrome; Ritonavir; Spain; Treatment Outcome | 2021 |
Use of Intravenous Immunoglobulin (Prevagen or Octagam) for the Treatment of COVID-19: Retrospective Case Series.
Topics: Adenosine Monophosphate; Adrenal Cortex Hormones; Adult; Aged; Alanine; Anti-Bacterial Agents; Antibodies, Monoclonal, Humanized; Antiviral Agents; APACHE; Azithromycin; COVID-19; COVID-19 Drug Treatment; Doxycycline; Enzyme Inhibitors; Extracorporeal Membrane Oxygenation; Female; Humans; Hydroxychloroquine; Immunoglobulins, Intravenous; Immunologic Factors; Intensive Care Units; Length of Stay; Lopinavir; Male; Middle Aged; Respiration, Artificial; Retrospective Studies; Severity of Illness Index; Time Factors; Young Adult | 2020 |
A retrospective comparison of drugs against COVID-19.
Topics: Adrenal Cortex Hormones; Adult; Aged; Aged, 80 and over; Antibodies, Viral; COVID-19; COVID-19 Drug Treatment; Drug Combinations; Female; Humans; Hydroxychloroquine; Immunoglobulin G; Immunoglobulin M; Indoles; Length of Stay; Lopinavir; Male; Middle Aged; Oseltamivir; Retrospective Studies; Ritonavir; SARS-CoV-2; Young Adult | 2021 |
Update to living WHO guideline on drugs for covid-19.
Topics: Antiviral Agents; COVID-19; COVID-19 Drug Treatment; Drug Combinations; Humans; Hydroxychloroquine; Lopinavir; Practice Guidelines as Topic; Ritonavir; SARS-CoV-2; World Health Organization | 2020 |
Early clinical outcomes with tocilizumab for severe COVID-19: a two-centre retrospective study.
Topics: Antibodies, Monoclonal, Humanized; Antiviral Agents; COVID-19; COVID-19 Drug Treatment; Critical Illness; Female; Humans; Hydroxychloroquine; Lopinavir; Male; Middle Aged; Oxygen; Retrospective Studies; Ritonavir; Time Factors; Treatment Outcome | 2021 |
Real-world prevalence and consequences of potential drug-drug interactions in the first-wave COVID-19 treatments.
Topics: Adjuvants, Immunologic; Aged; Antibodies, Monoclonal, Humanized; Cohort Studies; COVID-19; COVID-19 Drug Treatment; Cytochrome P-450 CYP3A Inhibitors; Drug Interactions; Enzyme Inhibitors; Female; Humans; Hydroxychloroquine; Interferon beta-1b; Lopinavir; Male; Prevalence; Retrospective Studies; Risk Factors; Ritonavir; SARS-CoV-2 | 2021 |
SARS-CoV-2 related pneumonia in an adult with cystic fibrosis: natural favourable clinical course or effective therapy?
Topics: Adult; Antibodies, Monoclonal, Humanized; Antiviral Agents; COVID-19; COVID-19 Drug Treatment; Cystic Fibrosis; Drug Combinations; Humans; Hydroxychloroquine; Lopinavir; Lung; Male; Oxygen Inhalation Therapy; Pneumonia, Viral; Receptors, Interleukin-6; Respiratory Function Tests; Respiratory Tract Infections; Ritonavir; SARS-CoV-2; Tomography, X-Ray Computed; Treatment Outcome | 2020 |
Early experimental COVID-19 therapies: associations with length of hospital stay, mortality and related costs.
Topics: Adolescent; Adult; Age Factors; Aged; Aged, 80 and over; Antiviral Agents; Child; Child, Preschool; Comorbidity; COVID-19; COVID-19 Drug Treatment; Drug Combinations; Drug Therapy, Combination; Health Expenditures; Hospital Mortality; Humans; Hydroxychloroquine; Infant; Length of Stay; Lopinavir; Middle Aged; Pandemics; Retrospective Studies; Ritonavir; SARS-CoV-2; Severity of Illness Index; Sex Factors; Socioeconomic Factors; Therapies, Investigational; Young Adult | 2020 |
Antiviral activity of interferon-based combination therapy in critically ill patients with COVID-19: Preliminary observations.
Topics: Antiviral Agents; COVID-19; COVID-19 Drug Treatment; Critical Illness; Drug Therapy, Combination; Humans; Hydroxychloroquine; Interferon beta-1a; Interferons; Lopinavir; Ritonavir; SARS-CoV-2; Viral Load | 2021 |
Can we use hydroxychloroquine to treat COVID-19 now?
Topics: Anti-Bacterial Agents; Antimalarials; Antiviral Agents; Azithromycin; Clinical Trials as Topic; COVID-19; COVID-19 Drug Treatment; Drug Combinations; Drug Repositioning; Humans; Hydroxychloroquine; Indoles; Interferon-alpha; Lopinavir; Ritonavir; SARS-CoV-2; Uncertainty | 2021 |
Network analysis and molecular mapping for SARS-CoV-2 to reveal drug targets and repurposing of clinically developed drugs.
Topics: Antiviral Agents; Ascorbic Acid; COVID-19; COVID-19 Drug Treatment; Drug Development; Drug Repositioning; Drug Therapy, Combination; Humans; Hydroxychloroquine; Lopinavir; Molecular Docking Simulation; Molecular Dynamics Simulation; Protein Binding; Protein Interaction Mapping; Protein Interaction Maps; Ritonavir; SARS-CoV-2; Signal Transduction; Virus Replication | 2021 |
Missing clinical trial data: the evidence gap in primary data for potential COVID-19 drugs.
Topics: Amides; Antiviral Agents; Clinical Trials as Topic; COVID-19 Drug Treatment; Drug Combinations; Drug Repositioning; Enzyme Inhibitors; Evidence-Based Medicine; Humans; Hydroxychloroquine; Lopinavir; PubMed; Pyrazines; Registries; Research Design; Research Report; Ritonavir; SARS-CoV-2 | 2021 |
Efficacy of canakinumab in mild or severe COVID-19 pneumonia.
Topics: Aged; Antibodies, Monoclonal, Humanized; Antiviral Agents; Combined Modality Therapy; COVID-19; COVID-19 Drug Treatment; Drug Therapy, Combination; Female; Humans; Hydroxychloroquine; Interleukin-1beta; Lopinavir; Male; Middle Aged; Molecular Targeted Therapy; Oxygen Inhalation Therapy; Pandemics; Ritonavir; SARS-CoV-2; Treatment Outcome | 2021 |
Azithromycin, a questionable treatment for COVID-19.
Topics: Azithromycin; COVID-19 Drug Treatment; Drug Combinations; Drug Therapy, Combination; Humans; Hydroxychloroquine; Lopinavir; Methylprednisolone; Ritonavir; SARS-CoV-2 | 2021 |
In inpatients with COVID-19, none of remdesivir, hydroxychloroquine, lopinavir, or interferon β-1a differed from standard care for in-hospital mortality.
Topics: Adenosine Monophosphate; Aged; Alanine; Antiviral Agents; COVID-19; COVID-19 Drug Treatment; Drug Therapy, Combination; Female; Hospital Mortality; Hospitalization; Humans; Hydroxychloroquine; Intention to Treat Analysis; Interferon beta-1a; Kaplan-Meier Estimate; Length of Stay; Lopinavir; Male; Middle Aged; Multicenter Studies as Topic; Randomized Controlled Trials as Topic; Respiration, Artificial; Treatment Failure; World Health Organization | 2021 |
Prevalence and correlates of chronic fatigue syndrome and post-traumatic stress disorder after the outbreak of the COVID-19.
Topics: Adult; Aged; Antiviral Agents; Cough; COVID-19; COVID-19 Drug Treatment; Dementia; Drug Combinations; Dyspnea; Fatigue Syndrome, Chronic; Female; Fever; Humans; Hydroxychloroquine; Lopinavir; Male; Middle Aged; Oseltamivir; Research Design; Ritonavir; SARS-CoV-2; Severity of Illness Index; Stress Disorders, Post-Traumatic; Surveys and Questionnaires; Survivors | 2021 |
Simultaneous quantification of seven repurposed COVID-19 drugs remdesivir (plus metabolite GS-441524), chloroquine, hydroxychloroquine, lopinavir, ritonavir, favipiravir and azithromycin by a two-dimensional isotope dilution LC-MS/MS method in human serum
Topics: Adenosine; Adenosine Monophosphate; Alanine; Amides; Antiviral Agents; Azithromycin; Chloroquine; Chromatography, Liquid; COVID-19; COVID-19 Drug Treatment; Furans; Humans; Hydroxychloroquine; Isotopes; Lopinavir; Pandemics; Pyrazines; Pyrroles; Ritonavir; SARS-CoV-2; Tandem Mass Spectrometry; Triazines | 2021 |
A COVID-19 pregnant patient with thrombotic thrombocytopenic purpura: a case report.
Topics: Acute Kidney Injury; Amphetamine-Related Disorders; Antiviral Agents; COVID-19; Drug Combinations; Erythrocyte Transfusion; Female; Hemoglobins; Humans; Hydroxychloroquine; Intensive Care Units; L-Lactate Dehydrogenase; Lopinavir; Methamphetamine; Plasmapheresis; Pregnancy; Pregnancy Complications, Hematologic; Pregnancy Complications, Infectious; Purpura, Thrombotic Thrombocytopenic; Renal Dialysis; Ritonavir; SARS-CoV-2; Stillbirth; Tomography, X-Ray Computed; Young Adult | 2021 |
Prolonged SARS-CoV-2 viral shedding in patients with solid tumours and associated factors.
Topics: Adenosine Monophosphate; Aged; Alanine; Antineoplastic Agents; Antiviral Agents; Breast Neoplasms; COVID-19; COVID-19 Drug Treatment; COVID-19 Nucleic Acid Testing; COVID-19 Serological Testing; COVID-19 Serotherapy; Dexamethasone; Drug Combinations; Female; Follow-Up Studies; Glucocorticoids; Humans; Hydroxychloroquine; Immunization, Passive; Immunotherapy; Latent Infection; Lopinavir; Lung Neoplasms; Male; Molecular Targeted Therapy; Neoplasms; Proportional Hazards Models; Risk Factors; Ritonavir; SARS-CoV-2; Spain; Time Factors; Virus Shedding | 2021 |
Smartphone electrocardiogram for QT interval monitoring in Coronavirus Disease 2019 (COVID-19) patients treated with Hydroxychloroquine.
Topics: Adult; Aged; Antiviral Agents; COVID-19 Drug Treatment; Drug Combinations; Electrocardiography; Enzyme Inhibitors; Female; Humans; Hydroxychloroquine; Long QT Syndrome; Lopinavir; Male; Middle Aged; Mobile Applications; Ritonavir; Smartphone | 2021 |
Phylogenic analysis of coronavirus genome and molecular studies on potential anti-COVID-19 agents from selected FDA-approved drugs.
Topics: Anti-Bacterial Agents; Antimalarials; Antiviral Agents; Coronavirus Nucleocapsid Proteins; COVID-19 Drug Treatment; Esterases; Hemagglutinins; Humans; Hydroxychloroquine; Levofloxacin; Ligands; Lopinavir; Molecular Docking Simulation; Molecular Dynamics Simulation; SARS-CoV-2 | 2022 |
Electronic monitoring of potential adverse drug events related to lopinavir/ritonavir and hydroxychloroquine during the first wave of COVID-19.
Topics: COVID-19; COVID-19 Drug Treatment; Drug-Related Side Effects and Adverse Reactions; Humans; Hydroxychloroquine; Lopinavir; Ritonavir; SARS-CoV-2 | 2023 |
Epidemiology, clinical characteristics, and treatment outcomes of patients with COVID-19 at Thailand's university-based referral hospital.
Topics: Adult; Aged; Aged, 80 and over; Amides; Antiviral Agents; Chloroquine; COVID-19; COVID-19 Drug Treatment; Darunavir; Disease Progression; Drug Combinations; Female; Hospitals; Hospitals, University; Humans; Hydroxychloroquine; Lopinavir; Male; Middle Aged; Pyrazines; Referral and Consultation; Retrospective Studies; Ritonavir; Thailand; Treatment Outcome; Young Adult | 2021 |
Cerebrospinal fluid and serum interleukins 6 and 8 during the acute and recovery phase in COVID-19 neuropathy patients.
Topics: Action Potentials; Acute Disease; Aged; Anti-Bacterial Agents; Biomarkers; Convalescence; COVID-19; COVID-19 Drug Treatment; Darunavir; Drug Combinations; Guillain-Barre Syndrome; Humans; Hydroxychloroquine; Immunoglobulins, Intravenous; Interleukin-6; Interleukin-8; Lopinavir; Male; Neural Conduction; Peripheral Nervous System; Prognosis; Respiratory Insufficiency; Ritonavir; SARS-CoV-2 | 2021 |
Antiviral treatment selection for SARS-CoV-2 pneumonia.
Topics: Antiviral Agents; COVID-19; Humans; Hydroxychloroquine; Lopinavir; SARS-CoV-2; Treatment Outcome | 2021 |
Therapy with lopinavir/ritonavir and hydroxychloroquine is associated with acute kidney injury in COVID-19 patients.
Topics: Acute Kidney Injury; Aged; Antiviral Agents; COVID-19; COVID-19 Drug Treatment; Creatinine; Drug Therapy, Combination; Female; Germany; Humans; Hydroxychloroquine; Incidence; Intensive Care Units; Lopinavir; Male; Middle Aged; Retrospective Studies; SARS-CoV-2 | 2021 |
Use of repurposed and adjuvant drugs in hospital patients with covid-19: multinational network cohort study.
Topics: Administrative Claims, Healthcare; Adolescent; Adrenal Cortex Hormones; Adult; Aged; Aged, 80 and over; Azithromycin; Ceftriaxone; Chemotherapy, Adjuvant; Child; Child, Preschool; China; Cohort Studies; COVID-19; COVID-19 Drug Treatment; Drug Combinations; Drug Repositioning; Electronic Health Records; Enoxaparin; Female; Fluoroquinolones; Humans; Hydroxychloroquine; Infant; Infant, Newborn; Inpatients; Lopinavir; Male; Middle Aged; Republic of Korea; Ritonavir; Safety; SARS-CoV-2; Spain; Treatment Outcome; United States; Vitamin D; Young Adult | 2021 |
Drug-drug interactions between treatment specific pharmacotherapy and concomitant medication in patients with COVID-19 in the first wave in Spain.
Topics: Aged; Analgesics; Cardiovascular Diseases; Cohort Studies; COVID-19; COVID-19 Drug Treatment; Diuretics; Drug Interactions; Female; Humans; Hydroxychloroquine; Lopinavir; Male; Middle Aged; Nervous System Diseases; Polypharmacy; Risk Factors; Ritonavir; SARS-CoV-2; Severity of Illness Index; Spain | 2021 |
QT Interval Monitoring with Handheld Heart Rhythm ECG Device in COVID-19 Patients.
Topics: Aged; Aged, 80 and over; Anti-Bacterial Agents; Antiviral Agents; Azithromycin; COVID-19 Drug Treatment; Drug Combinations; Electrocardiography; Enzyme Inhibitors; Feasibility Studies; Female; Humans; Hydroxychloroquine; Long QT Syndrome; Lopinavir; Male; Middle Aged; Point-of-Care Systems; Prospective Studies; Reproducibility of Results; Ritonavir; SARS-CoV-2 | 2021 |
Corrected QT interval in hospitalized patients with coronavirus disease 2019: Focus on drugs therapy.
Topics: Aged; Antiviral Agents; Chloroquine; COVID-19; COVID-19 Drug Treatment; Drug Therapy, Combination; Drugs, Chinese Herbal; Electrocardiography; Female; Hospital Mortality; Hospitalization; Humans; Hydroxychloroquine; Indoles; Interferons; Long QT Syndrome; Lopinavir; Male; Middle Aged; Odds Ratio; Quinolones; Retrospective Studies; Ritonavir; SARS-CoV-2; Severity of Illness Index | 2021 |
Comparison of demographic and clinical characteristics of hospitalized COVID-19 patients with severe/critical illness in the first wave versus the second wave.
Topics: Aged; Amides; Antibodies, Monoclonal, Humanized; Azithromycin; C-Reactive Protein; Comorbidity; COVID-19; COVID-19 Drug Treatment; Critical Care; Drug Combinations; Enoxaparin; Female; Hospital Mortality; Hospitalization; Humans; Hydroxychloroquine; Interleukin 1 Receptor Antagonist Protein; Lopinavir; Male; Methylprednisolone; Middle Aged; Pyrazines; Retrospective Studies; Ritonavir; SARS-CoV-2; Severity of Illness Index; Treatment Outcome; Turkey | 2022 |
Severe COVID-19 infection in a kidney transplant recipient treated with lopinavir/ritonavir, hydroxychloroquine and dexamethasone.
Topics: Aged; COVID-19 Drug Treatment; Dexamethasone; Drug Combinations; Female; Humans; Hydroxychloroquine; Immunosuppressive Agents; Kidney Transplantation; Lopinavir; Ritonavir; Transplant Recipients | 2021 |
Understanding the binding mechanism for potential inhibition of SARS-CoV-2 Mpro and exploring the modes of ACE2 inhibition by hydroxychloroquine.
Topics: Adenosine Monophosphate; Alanine; Angiotensin-Converting Enzyme 2; Antiviral Agents; Binding Sites; Catalytic Domain; Coronavirus 3C Proteases; COVID-19 Drug Treatment; Datasets as Topic; Drug Repositioning; Energy Transfer; Humans; Hydroxychloroquine; Lopinavir; Models, Molecular; Molecular Docking Simulation; Molecular Dynamics Simulation; Protein Binding; Protein Conformation; Receptors, Virus; Ritonavir; SARS-CoV-2 | 2022 |
Off-Label Use of Hydroxychloroquine in COVID-19: Analysis of Reports of Suspected Adverse Reactions From the Italian National Network of Pharmacovigilance.
Topics: Azithromycin; COVID-19 Drug Treatment; Diarrhea; Drug-Related Side Effects and Adverse Reactions; Humans; Hydroxychloroquine; Long QT Syndrome; Lopinavir; Off-Label Use; Pharmacovigilance; Ritonavir | 2022 |
Comparing Outcomes of Two Antiviral Therapy Combinations among COVID-19 Patients.
Topics: Aged; Antiviral Agents; Arrhythmias, Cardiac; Atazanavir Sulfate; Bilirubin; COVID-19; COVID-19 Drug Treatment; Drug Combinations; Drug Therapy, Combination; Female; Hospitalization; Humans; Hydroxychloroquine; Length of Stay; Lopinavir; Male; Middle Aged; Ritonavir; SARS-CoV-2; Treatment Outcome | 2022 |
High-cited favorable studies for COVID-19 treatments ineffective in large trials.
Topics: Azithromycin; Colchicine; COVID-19 Drug Treatment; COVID-19 Serotherapy; Humans; Hydroxychloroquine; Interferons; Lopinavir; Ritonavir | 2022 |
Emerging Therapies for COVID-19: The Value of Information From More Clinical Trials.
Topics: Antibodies, Monoclonal, Humanized; Cost-Benefit Analysis; COVID-19 Drug Treatment; Dexamethasone; Humans; Hydroxychloroquine; Interferon beta-1a; Lopinavir; Quality-Adjusted Life Years; Randomized Controlled Trials as Topic; Ritonavir | 2022 |
Use of combined treatment of 3rd-generation cephalosporin, azithromycin and antiviral agents on moderate SARs-CoV-2 patients in South Korea: A retrospective cohort study.
Topics: Anti-Bacterial Agents; Antiviral Agents; Azithromycin; Cephalosporins; COVID-19 Drug Treatment; Humans; Hydroxychloroquine; Lopinavir; Retrospective Studies; Ritonavir; SARS-CoV-2; Treatment Outcome | 2022 |
Agreement of treatment effects from observational studies and randomized controlled trials evaluating hydroxychloroquine, lopinavir-ritonavir, or dexamethasone for covid-19: meta-epidemiological study.
Topics: COVID-19 Drug Treatment; Dexamethasone; Humans; Hydroxychloroquine; Lopinavir; Meta-Analysis as Topic; Observational Studies as Topic; Randomized Controlled Trials as Topic; Ritonavir | 2022 |
Effects of Drugs Formerly Suggested for COVID-19 Repurposing on Pannexin1 Channels.
Topics: Connexins; COVID-19 Drug Treatment; Drug Repositioning; Humans; Hydroxychloroquine; Inflammation; Lopinavir; Nerve Tissue Proteins; Ritonavir; RNA, Messenger | 2022 |
Quality of hospital emergency department care for patients with COVID-19 during the first wave in 2020: the CALUR-COVID-19 study.
Topics: COVID-19; Emergency Service, Hospital; Hospitals; Humans; Hydroxychloroquine; Lopinavir; Ritonavir; SARS-CoV-2 | 2022 |
[Pharmacoepidemiological research of COVID-19 in the Russian Federation EGIDA-2020].
Topics: Adult; Anti-Bacterial Agents; Antiviral Agents; COVID-19; Female; Humans; Hydroxychloroquine; Interferons; Lopinavir; Male; Middle Aged; Retrospective Studies; Ritonavir; SARS-CoV-2; Young Adult | 2021 |
Long-term (180-Day) Outcomes in Critically Ill Patients With COVID-19 in the REMAP-CAP Randomized Clinical Trial.
Topics: Adrenal Cortex Hormones; Adult; Anticoagulants; Bayes Theorem; COVID-19; COVID-19 Serotherapy; Critical Illness; Female; Follow-Up Studies; Humans; Hydroxychloroquine; Lopinavir; Male; Middle Aged; Receptors, Interleukin-6; Ritonavir; SARS-CoV-2 | 2023 |
Concerted and multidisciplinary management of COVID-19 drug therapies during the first two epidemic waves in a tertiary hospital in Marseille, France: Results of the PHARMA-COVID study.
Topics: Aged; Antiviral Agents; COVID-19; COVID-19 Drug Treatment; Humans; Hydroxychloroquine; Lopinavir; Ritonavir; SARS-CoV-2; Tertiary Care Centers | 2023 |